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Cervical cancer is the second most common type of cancer in women worldwide.  
Because cervical cancer is usually asymptomatic until the disease is in its advanced stages, 
cervical screening is of central importance towards combating cervical cancer.  Alternative 
screening strategies are evaluated from an economic point of view through cost-
effectiveness analysis.  In the literature however, studies perform cost-effectiveness 
analysis on a limited number of de facto or predetermined screening policies.  At present, 
no attempt has been made to construct efficient screening strategies through optimization, 
  ix 
before cost-effectiveness analysis is applied.  In this study simulation optimization is used 
to construct efficient screening strategies for cervical cancer by properly timing the 
screenings.  The constructed strategies are highly cost-effective when a small number of 
lifetime screenings is available, and are more cost-effective than screening strategies used 
in practice or considered in the literature so far, indicating the value of optimal timing for 
other screened diseases as well.
  1 
 
 
 
 
CHAPTER 1 Introduction 
 
 
Cervical cancer is the second most common type of cancer in women worldwide 
(NCI 2007).  It is estimated that in the United States 11,150 women will be diagnosed with 
and 3,650 will die of cervical cancer in 2007 (NCI 2007).  Because symptoms in cervical 
cancer may be absent until the disease is in its advanced stages, it has become the focus of 
intense screening, primarily through Papanicolaou (Pap) smears.  The purpose of screening 
is to detect abnormal cells in the cervix before they develop to cancer where treatment is 
simple and effective, or to at least identify the cancer early in order to reduce mortality and 
suffering from it.  
Because of the central role of screening towards combating cervical cancer, 
developing methods that maximize its effect is essential and can be achieved primarily in 
two ways.  One way is by improving the effectiveness of the screening methods 
themselves through new technologies and new understandings, which may result to the 
improvement of existing screening methods, or the development of new ones.  The second 
way, which is also the goal of this study, is the development of screening strategies which 
utilize screenings the best way possible, and hence prevent cervical cancer incidence and 
improve quality of life in a cost-effective manner.  In this study, simulation optimization is 
used on a model that simulates the natural history of cervical carcinogenesis in order to 
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construct efficient screening strategies (i.e., screening strategies that provide the best 
possible benefits for a specific amount of recourses).  Up to present, cervical cancer 
screening studies only analyzed the cost-effectives of predetermined screening strategies; 
no attempt has been made to use optimization to construct screening strategies.  In order to 
achieve this, it is important to become first familiar first with cervical cancer, its natural 
history, the various methods of screening used, and the methods of treatment of 
precancerous cells and cancer.   
 
1.1 Cancer 
 Cancer refers to a group of diseases where damaged DNA in cells causes them to 
divide and grow in an uncontrolled fashion.  The uncontrolled growth causes a tumor to 
form, but a tumor does not necessarily imply cancer.  A benign tumor refers to all tumors 
that are not cancers.  Benign tumors contain cells that are very similar to normal cells. In 
order for a tumor to be classified as cancer it needs to be a malignant tumor.  Malignant 
tumors are composed of cancerous cells that have the following properties: the cells are 
aggressive (they divide and grow in an uncontrolled way), invasive (they spread and 
destroy surrounding cells), and sometimes metastatic (they spread to other parts of the 
body and cause cancer there as well).  
There are at least 200 types of cancer, which is approximately as many as the types 
of cells in the human body.  Although cancer cells can metastasize and cause cancer in 
other parts of the body, the cancer is always named after the place it originated.  The place 
where the cancer originated is called primary cancer.  Tumors from metastasized cells are 
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called secondary cancers.  Different types of cancer have different degrees of 
aggressiveness, invasiveness and different probabilities to metastasize.  Different types of 
cancer also have different symptoms and behave differently to different types of treatments 
like chemotherapy and radiation. 
 
1.2 Cervix and Cervical Cancer 
Cervical cancer (or cancer of the cervix uteri) is cancer on the cervix.  The cervix is 
a narrow, tube-like portion of the uterus that connects it with the vagina.  Cervix means 
“neck” in Latin, so “cervix uteri” means “neck of the uterus.”  Approximately half its 
length is visible with appropriate medical equipment; the remainder lies above the vagina, 
and beyond view.  Figure 1 shows the cervix as part of the woman’s reproductive system. 
 
             Figure 1: Female Reproductive System and the Cervix (CHUK 2007) 
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 The cervix is separated into the ectocervix which is made up of skin-like cells and 
the endocervix, which lies underneath which is made up of glandular cells.  Since they are 
different cells, they can have different types of cancer.  Cancer on the extocervix is called 
squamous cell cervical cancer, which is the most common type.  Cancer on the endocervix 
is called adenocarcinoma of the cervix.  Medical treatment for both cancers is the same. 
The area where cervical cells are most likely to become cancerous is called the 
transformation zone, which can also be seen in Figure 1.  
 
1.3 Risks and Causes of Cervical Cancer 
 A risk factor is anything that increases a person's chance of getting a disease.  
There are many risk factors for cervical cancer, but the most important one is the human 
papilloma virus (HPV).  HPV refers to a group of viruses.  There are more than 100 types, 
or strains, of HPV, only some of which cause cervical cancer.  Other strains cause other 
diseases such as skin warts and genital warts.  HPV types that can cause cervical cancer are 
called oncogenic or high risk types.  In recent studies, HPV DNA has been detected in up 
to 99.7% of all cervical cancers, and infection with one of four high risk types of HPV 
(i.e., 16, 18, 45, and 31) accounts for approximately 75% of all cervical cancer diagnosed 
each year (Goldie et al. 2004).  This essentially makes oncogenic HPV a necessary cause 
of cervical cancer.  HPV is a sexually transmitted disease (STD), therefore women who 
have unprotected sex or many sexual partners have a greater chance of getting oncogenic 
HPV, and hence, cervical cancer (NCI, 2007).  Although oncogenic HPV is an important 
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risk factor for cervical cancer, most cases do not develop to cervical cancer but are 
naturally eliminated by the immune system.  Therefore, other risk factors are still 
important to the development of cervical cancer by acting as catalysts and hence increasing 
the risk of HPV progressing to the development abnormal cells and possibly cancer.  The 
most important such factors are smocking, diet, having a weakened immune system (due to 
HIV infection, for example), having many children, and family history.  
1.4 Symptoms Associated with Cervical Cancer 
 Precancerous abnormal cells are usually asymptomatic.  Furthermore, early stages 
of cervical cancer are often asymptomatic as well.  That is why cervical cancer has been 
the focus of intense screening for prevention, which will be the focus of Section 1.6.  The 
most common symptom of cervical cancer is bleeding from the vagina at times other than 
during menstruation (i.e., between menstrual cycles, during or after sexual intercourse, at 
any time past menopause).  Some other symptoms are discomfort or pain during sexual 
intercourse, and vaginal discharge with an unpleasant smell.  It is important to note 
however that many other conditions have these symptoms that are also more common than 
cervical cancer (NCI 2007, CHUK 2007). 
 
1.5 Natural History of Cervical Carcinogenesis 
Virtually all cases of cervical cancer begin with an HPV infection.  If HPV is 
oncogenic, it may progress to precancerous abnormal cells called cervical intraepithelial 
neoplasia (CIN).  There are three levels of CIN, each one referring to the thickness of the 
  6 
skin covering the cervix that is affected.  CIN I refers to mild cell changes, where one third 
of the thickness of the skin covering the cervix has abnormal cells.  CIN II refers to 
moderate cell changes, where two thirds of the thickness of the skin covering the cervix 
has abnormal cells.  CIN III (also called carcinoma in situ (CIC)) refers to severe cell 
changes, where the full thickness of the skin covering the cervix has abnormal cells.  CIN 
III means that some of the cells look cancerous, but they are all contained within the skin 
covering the cervix and do not invade surrounding tissue.  Within each of these stages the 
disease may progress to the next state, or it may be naturally eliminated by the immune 
system (i.e., it regresses), which occurs most of the time.  
  Once the disease reaches cancerous levels, however, the chance of the immune 
system eliminating the disease is virtually nonexistent.  Cervical cancer has four stages 
called FIGO stages, FIGO I-IV, which indicate how far the cancer has spread.  FIGO is an 
acronym for Fédération Internationale de Gynécologie et d'Obstétrique; the French name 
of the International Federation of Gynecology and Obstetrics.  FIGO I stage indicates that 
the cancer is limited to the cervix.  FIGO II indicates that the cancer invaded cells around 
the cervix; it invaded the upper part of the vagina and maybe the womb.  FIGO III 
indicates that the cancer has spread away from the area surrounding the cervix; it extends 
to the pelvic wall, or the lower third of the vagina, or it may have also grown up to 
block the tubes that drain the kidneys (the ureters).  FIGO IV indicates that the cancer has 
spread to other body organs outside the cervix and the womb.  Further subdivisions of 
these stages also exist. (NCI 2007, CHUK 2007) 
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1.6 Cervical Cancer Screening and Prevention  
1.6.1 Screening 
 Screening in the medical context refers to strategies that are performed on 
individuals that do not have any symptoms of disease.  The goal of screening is to identify 
a disease early so that it allows treatment at early stages, which ideally results in reduced 
mortality and suffering from the disease.  This is not always the case, however.  
Sometimes it is ambiguous whether the benefits of screening outweigh the costs that arise 
from performing diagnostic tests and treatments.  For example, if a screening strategy 
detects a disease at early stages with a small chance of progressing and treatment is 
imposed, the risks involved in screening and treatment (such as surgery or chemotherapy) 
may not result in an overall reduced suffering and mortality from that disease.  Such a 
situation is called overdiagnosis.  Other adverse effects of screening include stress caused 
from false positive results and waste of medical recourses that are associated with them, 
resources that could have been better used elsewhere.  
Screening methods must be relatively inexpensive, safe, and have high specificity 
and sensitivity, especially for diseases with low incidence.  Specificity of a test is the 
conditional probability that the test will indicate that the disease is not present, provided 
that the disease is indeed not present.  Sensitivity of a test is the conditional probability that 
the test will indicate that the disease is present, provided that the disease is indeed present.  
In other words, they are the conditional probabilities that a test will result at a true negative 
and a true positive, respectively.  
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1.6.2 Screening for Cervical Cancer 
 The most widely used method of screening for cervical cancer is the Papanicolaou 
test (Pap smear), which can detect abnormal cells, ideally, before they have a chance to 
develop to cancer.  Treatments at precancerous levels are simple, less intrusive, more 
effective, and less costly.  The Pap smear is a beneficial screening method since it is safe, 
easy to perform, and relatively inexpensive.  In addition, since cervical cancer has a slow 
progression, it allows more time for screening to catch the disease early, at precancerous 
stages.  Pap smears are performed by the doctor placing a speculum inside the vagina 
which has arms that spread the sides of the vagina and allows the doctor to clearly see the 
cervix.  Then skin cells are collected from the cervix by scrapping the surface of the cervix 
with a spatula or brush.  As soon as the sample is taken it is spread on a glass slide and sent 
to a laboratory to check for presence of abnormal cells by putting them under a 
microscope.  The procedure is depicted in Figure 2.  A new way of performing the test is 
placing the cells into a pot of liquid, which preserves the cells, instead on a slide.  This is 
called liquid based cytology as opposed to conventional cytology screening. 
 
 
Figure 2: Depiction of a Pap smear Test (FVIVF 2007) 
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The general guidelines for Pap smears in the United States are that women should 
start screening at the age of 21 or three years after they become sexually active, whichever 
occurs first.  Pap smears should be performed at least every three years.  Women 65 to 70 
years old who have had three abnormal screenings and no normal screenings in 10 years 
may stop having screenings after consulting with their doctor (NCI 2007).  Women who 
have had a total benign hysterectomy, (i.e., hysterectomy that was not performed to 
remove precancerous cells or cancer) do not need screening (NCI 2007).  
Other screening methods for cervical cancer are HPV DNA testing for high risk 
types of HPV and visual inspection of the cervix after applying acetic acid.  Each method 
is associated with different costs and different specificity and sensitivity levels.  Given this, 
many mathematical model studies have focused in comparing the cost-effectiveness, (i.e., 
the ratio of the expected costs over the expected benefits) of different strategies using 
different screening methods (Mandelblatt et al. 2002a).  Even though Pap smears are the 
standard method of screening in developed countries, mathematical model studies have 
shown that in developing countries or low-recourse settings visual inspection and HPV 
DNA strategies are cost-effective alternatives to Pap smear screening (Goldie et al. 2005, 
Mandelblatt et al. 2002b).   
 
1.6.3 Cervical Cancer Prevention 
  Recently, vaccines that prevent specific high risk HPV strains have been 
developed.  Currently there are two such vaccines available, Gardasil and Cervarix. 
Gardasil was approved by the Food and Drug Administration (FDA) in 2006 and was also 
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approved by the European Union.  Cervarix’s FDA approval procedures are still underway, 
and it has been approved in Australia and the Philippines in 2007.  Both vaccines prevent 
infection of high risk HPV types 16 and 18 which account for about 70% of all cervical 
cancers (NCI, 2007).  Gardasil also prevents HPV types 6 and 11 which cause about 90% 
of genital wart cases (NCI, 2007).  The vaccine is targeted at adolescent girls aged twelve 
years old because they have shown to have a better serological response to the vaccine 
compared with older women, which theoretically leads to longer immunity (Adams et al. 
2007).  Also the vaccine works only if it is given before an HPV infection occurs.  Because 
the vaccines have been recently developed, there is little to no empirical information to the 
cost-effectiveness of the vaccines either by themselves or in conjunction with screening 
strategies.  That is why many mathematical model studies have projected the clinical 
benefits and cost-effectiveness of such vaccines (Goldie et al. 2003, Goldie et al. 2004).  
 
1.7 Treatments for Abnormal Cells 
 If a Pap smear result is positive, it reports the level of abnormal cells by stating the 
level of CIN.  This classification is not strictly accurate, however, as the true CIN level can 
only be diagnosed with a biopsy which is done through a colposcopy.  Nonetheless, if the 
classification is CIN I, the doctor may ask the patient to come back for another Pap smear 
in six months instead of sending the patient to have a colposcopy or cone biopsy 
immediately.  If the results are CIN II or CIN III then the doctor will probably send the 
patient straight for colposcopy or cone biopsy. 
  11 
Colposcopy is simply a close up examination of the cervix through a magnifying 
glass that enables the doctor to see abnormalities that may be too small to see with the 
naked eye.  The doctor may take samples (i.e., biopsies) during colposcopy to send to a 
laboratory.  During a colposcopy, unlike during a Pap smear, the entire transformation area 
can be seen clearly which is where cervical cells are most likely to become cancerous.  If 
the patient clearly has abnormal cells seen with the colposcope, the abnormal cells may be 
treated the same time as the colposcopy to save the patient from making two trips to the 
hospital.  Cone biopsy refers to a minor operation where a biopsy of the cervix is taken in a 
cone-shaped sample.  It may be used either for diagnostic purposes, or for therapeutic 
purposes to remove pre-cancerous cells.  
If the results of the colposcopy or the cone biopsy are positive, the patient will be 
asked to return to the hospital to treat the abnormal cells.  A cone biopsy may have 
successfully removed the abnormal cells, however.  Once the abnormal cells are removed, 
the treatment is complete, but follow up Pap smears are usually performed six and twelve 
months after treatment for confirmation.  If all follow up Pap smears are negative, then the 
patient returns to her normal screening schedule.  
There are several treatments for precancerous abnormal cells, all of which try to 
remove or destroy the abnormal cells.  The following three treatments only treat the areas 
of the cervix where the abnormal cells reside; allowing normal cells to grow back:  
Laser ablation: A laser beam is pointed at the abnormal cells and burns them out.  It is 
done with a local anesthetic.  
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Cold coagulation: Abnormal cells are destroyed by a hot probe.  It is also done with local 
anesthetic. 
Cryotherapy: Abnormal cells are destroyer by a cold probe.  It is also done with local 
anesthetic. (CHUK 2007) 
The following three treatments remove the entire transformation zone; the area that 
contains all the cells that could become precancerous or develop to cancer (see Figure 1):    
LEEP stands for loop electrosurgical excision procedure.  It uses a small tool and electric 
current to remove the transformation zone from the cervix.  It is currently the most 
commonly used approach to treading precancerous abnormal cells.  It has the advantage 
that instead of destroying the cells, they are removed and sent to a laboratory to confirm 
that the area containing abnormal cells has been removed.  It is done with a local anesthetic 
and the procedure is often performed along with colposcopy.  
Cone biopsy: As already mentioned it is a small operation where a cone shaped section is 
taken from the cervix either to diagnose or treat abnormal cells or to diagnose cancer.  It is 
done under local or general anesthetic.  
Hysterectomy: If abnormal cells have been found on a patient’s cervix more than once, or 
if the abnormality is severe, the doctor may recommend hysterectomy.  In a hysterectomy 
the entire or part of the womb is removed, which, like the cervix, is also part of the female 
reproductive system and can be seen in Figure 1. (CHUK 2007) 
 Since there is some chance that not all affected cells were removed, patients need to 
continue check ups.  Usually a colposcopy or a Pap smear is performed six months after 
the treatment and a Pap smear twelve months after treatment.  After that, subsequent Pap 
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smears are performed depending on the amount of abnormal cells and if all of them have 
been successfully removed.  If abnormal cells reappear they are treated normally.  If they 
reappear more than once however a hysterectomy may be performed.  Very rarely, even 
after a hysterectomy, not all abnormal cells are removed so Pap smears are performed six 
and twelve months after treatment.  
 
1.8 Cervical Cancer Treatments  
 There are three treatment methods used in treating cervical cancer, surgery, 
radiotherapy, and chemotherapy.    
Surgery: Surgery as a treatment for cervical cancer refers to hysterectomy to remove the 
cervix and uterus.  Sometimes radical hysterectomy is needed where parts of the vagina are 
also removed.  
Radiotherapy: Radiotherapy uses high energy waves like X-rays and gamma rays to cure 
cancer.  It can be done externally from a machine outside the body or internally by placing 
radioactive material inside the womb focusing radiation near the cervix and lower part of 
the womb.  
Chemotherapy: Chemotherapy uses drugs that kill cancer cells by disturbing their growth.  
They are entered to the bloodstream through a vain so it can affect cancerous cells 
everywhere in the body. 
Different treatments or combinations of them are used at different states.  The 
chance of success of treatment is measured by the five-year survival rate, which refers to 
the proportion of people that are still alive five years after diagnosis and treatment.  The 
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chance of a person dying from cancer after five years is extremely small, that is why this 
time interval is used (Myers et al. 2000).  The five-year survival varies based on the overall 
well-being of the patient, the exact spread of the cancer, and it also increases as treatment 
methods are improved over time.  Below is a summary of the treatments used and their 
five-year survival rates for each state.  The estimated five-year survival rates are 
summarized from Siebert et. al. (2006), as they are some of the most recent estimates used 
in mathematical model studies. 
FIGO I is generally treated with surgery or radiotherapy.  If it is very advanced, combined 
chemotherapy and radiotherapy may be used.  The five-year survival rate is 94%. 
FIGO II is treated with surgery, radiotherapy, or both.  If advanced, combined radiotherapy 
and chemotherapy treatments are used.  The five-year survival rate is 73%.  
FIGO III is normally treated with combined use of radiotherapy and chemotherapy.  The 
five-year survival rate is 59%.  
FIGO IV is treated with surgery, radiotherapy, chemotherapy or a combination of them.  
The five-year survival rate is 23%.    
 
1.9 Research Objectives and Organization of Thesis  
 At present, no substantial attempt has been made to use simulation models to 
construct cost-effective screening strategies towards combating cervical cancer.  In most 
cases, simulation models were used to compare existing screening strategies, such as 
screening every two, three, and five years by performing cost-effectiveness analysis on 
these existing screening strategies.  In few cases, some intuition and experience about the 
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natural history of cervical carcinogenesis was used to consider different ages to start and 
end screening, and to find the best age to screen given one lifetime screening available for 
each woman.  In this thesis, multi-objective simulation optimization methods are applied 
on a model that simulates the natural history of cervical carcinogenesis, to construct 
efficient screening strategies.  Such strategies are more cost-effective than strategies that 
are used in practice or considered in the literature so far. 
 The organization of the remaining thesis is as follows:  Chapter 2 presents 
mathematical background information needed to perform the recommended analysis such 
as cost-effectiveness analysis, and Markov process models.  Then a literature review is 
performed along with an argument of the appropriateness of optimization as a means of 
constructing efficient screening strategies.  Chapter 3 provides a full description of the 
model that was constructed to simulate the natural history of cervical carcinogenesis, and 
of the formulation of the optimization models used to construct the screening strategies.  
Chapter 4 focuses on the analysis of the strategies given by the optimizations.  Chapter 5 
discusses overall conclusions and recommendations for further study. 
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CHAPTER 2 Cost-Effectiveness Analysis, Mathematical Models for 
Cervical Cancer Screening, and Simulation Optimization 
 
 
 This chapter begins with an overview of cost-effectiveness analysis as the 
appropriate method used in comparing different screening strategies.  Then, a discussion 
on the use of mathematical models as a method of considering different screening 
strategies is made, along with an overview of Markov processes, of which non-stationary 
Markov processes are the most appropriate models to accurately represent the natural 
history of cervical carcinogenesis.  Then, a literature review is performed to indicate how 
mathematical models have been used to study screening strategies for cervical cancer.  
Then, an argument on the need of optimization is made, indicating how it ties in with cost-
effectiveness analysis.  Finally, an overview of simulation optimization is provided.  
 
2.1 Cost-Effectiveness Analysis 
 When dealing with clinical interventions from an economic point of view, the most 
common method of comparison is cost-effectiveness analysis.  Cost-effectiveness analysis 
compares the expected costs and expected gains of two or more alterative courses of 
action.  Specifically for health issues, it compares the expected costs and health benefits of 
two or more clinical interventions.  It is important to distinguish the difference between 
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cost-effectiveness analysis and cost-minimization (i.e., optimization) analysis.  In cost 
minimization analysis, the goal is to achieve a particular task with the smallest costs 
possible.  In cost-effectiveness analysis, the goal is to see how much additional health 
benefits can be gained per dollar as more expensive alternatives are considered. 
 Cost-effectiveness is expressed by the incremental cost-effectiveness ratio (ICER), 
which is defined as the ratio of the difference of the expected costs, over the difference of 
the expected benefits of an efficient alternative, compared to the next best efficient 
alternative.  Its units of measurement are usually dollars per unit of health benefits gained.  
Mathematically ICER is expressed as follows:  
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where  
i = ranking of efficient alternative 
)( iCE  = the expected costs of the i
th best policy 
( )iE B  = the expected benefits of the i
th best policy 
Note that ICER is computed only with efficient alternatives.  An efficient (or non-
dominated) alternative is one that for a specific cost offers the most benefits. Such 
alternatives lie on the efficiency curve in the cost-effectiveness plane.  If an alternative 
costs more and is equally or less effective, or costs the same and it is less effective than 
some other alternative, it is said to be dominated and it lies inside the efficiency curve.  
Note that the cost-effectiveness ratio of an efficient alternative is calculated relative to the 
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next best efficient alternative.  If this is not the case, then there is a risk of incorrectly 
concluding that an alternative is cost-effective.  
The definition of ICER reiterates the goal of cost-effectiveness analysis, which 
studies the additional costs per health unit gained as more expensive alternatives are 
considered.  In cost-effectiveness analysis, the law of diminishing returns is also seen, 
since as more expensive alternatives are considered their ICER gets larger.  In other words, 
as the alternatives get more and more expensive, the amount of additional benefits per each 
additional dollar spent become less and less.  Once the efficiency curve is established, the 
decision maker can use it to decide at which alternative, the additional costs called for (for 
the next more expensive alternative) do not provide sufficient additional health benefits 
and choose that alternative for the specific problem in question.  
 
2.2 Randomized Clinical Trials, Cohort Studies, and Mathematical Models  
 Standard methods of measuring the effectiveness and cost-effectiveness of clinical 
interventions are randomized clinical trials and cohort studies.  A clinical trial is a test that 
compares one treatment versus another (or no treatment) by using an experimental and a 
control group of subjects respectively.  A cohort study is a type of a longitudinal study 
where a subgroup of a targeted group of people sharing a common characteristic is 
followed within a time period.  A birth cohort, for example, is a group of people who were 
born in the same year.  In both cases it is essential that the subjects are randomly selected 
so that they represent the general population of interest. 
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 When comparing the effectiveness and cost-effectiveness of clinical interventions 
such as alternative screening strategies, randomized clinical trials and cohort studies are 
not always practical, economically feasible, or ethical (Cantor et al. 2003).  In addition, 
such studies can be hindered by noncompliance and dropout by the subjects.  Furthermore, 
making intelligent decisions regarding clinical interventions require that all the parameters 
that come into play to be carefully considered.  This means taking into account parameters 
that determine the natural history of a disease, the clinical benefits, and costs of alternative 
interventions, information on the accessibility, compliance to treatment, and so forth.  A 
single cohort study or clinical trial cannot incorporate all of these components nor evaluate 
all possible strategies that could be considered (Goldie 2003).  
  Mathematical models join the best available information from different studies 
and synthesize them in a single model, so that all the information needed are considered 
(Goldie 2003).  Also, with mathematical models, otherwise infeasible hypothetical 
comparisons or questions can easily be considered.   In addition, mathematical models can 
not only simulate real life, but can do so at a much faster rate; a cohort of 1,000,000 
subjects for example can be simulated through the course of their entire lifespan in a matter 
of minutes.  Hence, mathematical models can extend and extrapolate results beyond the 
time-horizon of a clinical study.  Mathematical models can also deal with uncertainty 
involved in certain parameters, since those parameters can be varied within a plausible 
range of values and see the effect that has on the effectiveness of the clinical intervention. 
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2.3 Stochastic Models and Markov Processes 
 In order for mathematical models to aid in making decisions regarding clinical 
interventions, they must be able to cope with uncertainty.  This is because the parameters 
that they must incorporate are probabilistic in nature.  For example, some primary 
parameters in a disease prevention model are the risks of getting the disease and the risks 
of the disease progressing to more advanced stages.  Other core parameters in such models 
that are probabilistic are the specificity and sensitivity of different screening strategies, and 
the probabilities of effective treatment of a disease at its various stages.  Therefore, in 
order for a mathematical model to properly represent such a situation, it needs to be 
stochastic in nature.  Stochastic mathematical models are ones that use random variables 
for potential events to occur. 
A simple and commonly used stochastic model is a decision tree (or tree diagram). 
A decision tree uses a graph to depict a set of alternative decisions along with their 
possible outcomes, their respective probabilities of occurring, and their expected costs or 
benefits.  A decision tree however, allows decisions to be made about one future event, 
over a short time horizon.  When dealing with diseases however, there are many future 
events occurring over a long period of time.  Therefore, applying a decision tree to such a 
situation would result to oversimplifying the problem.  Decision trees were used in medical 
decision making until 1983, when Beck and Pauker indicated how the use of Markov 
models (which will be described later in this section), is a far more accurate representation 
of clinical settings (Sonnenberg et al. 1993).  
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 A probabilistic model for processes that evolve over time through multiple future 
events is called a stochastic process.  More formally, a stochastic process is defined as an 
indexed collection or random variables }{ tX  which represent the state of the system at 
time t.  The values of the random variables tX represent the state of the system at that time.  
If t can only attain discrete values and the number of possible states the process can be in is 
finite, then the process is called a discrete time stochastic process with a finite state space.  
For a cervical cancer stochastic process, t often obtains discrete values of one year 
intervals and the states of the process are the states a woman can be in with respect to 
cervical carcinogenesis as described in Section 1.5, at the end of each year during her 
lifetime.  Then, the sequence of states that a woman is year after year provides a 
mathematical representation of how her health status evolves over time.  
 In order to perform analysis with stochastic processes however, some additional 
assumptions need to be made.  One such assumption is called the Markov property.  A 
stochastic process }{ tX  is said to have the Markov property if the conditional probabilities 
of a process to transition to a state j at time t+1 given that it is on state i at time t, only 
depend on the state i at time t.  In other words, the transition probabilities do not depend on 
the past history of the process, but only on its current state.  More formally, the Markov 
property is expressed as follows: 
}|{},...,,|{ 100111 iXjXPiXiXiXjXP tttttt ======= +−−+ .  
A stochastic process that possesses the Markov property is called a Markov process and 
the transition probabilities are denoted by }|{ 1 iXjXPp ttij === + .  If these probabilities 
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do not change over time, then the Markov process is said to be stationary.  When this is the 
case the transition probabilities can be displayed in a square matrix SSP ×  called the one 
step transition matrix, where S is the number of states the process can be in.  In some cases 
however, the transition probabilities vary over time and the process is called a time-varying 
or a non-stationary Markov process.  In such a case the transition probabilities are denoted 
by }|{ 1 iXjXPp tt
t
ij === +  and there exists a transition matrix for each time t which we 
denote by t S SP × .  Therefore, the transition probabilities of a non-stationary Markov process 
can be thought of as a three dimensional matrix (or array), where t takes values as large as 
the time horizon considered for a specific model.  In both cases, because the process must 
make a transition into some state (which includes the system staying in the same state) the 
transition probabilities must satisfy the property 1
0
=∑
=
S
j
ijp for all i = 1,…, S.  Unlike 
stationary Markov processes, where closed-form solutions exist to answer various 
questions, non-stationary Markov processes do not generally have closed form solutions, 
so answers are often obtained by running simulation models of them over large samples.  
 Non-stationary Markov processes are the most appropriate tool for modeling 
diseases because the probabilities of acquiring the disease, and progressing to a more 
advanced stage, or regressing to a previous stage of the disease vary according on the age 
of the of the individuals.  This is also the case with cervical carcinogenesis.  Since HPV is 
a sexually transmitted disease, the probability of a woman getting infected depends on the 
patterns of sexual behavior in the population of interest which vary by age.  Also the 
probabilities of progression and regression of the disease to and from more advance stages 
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respectively, depend on the strength of the immune system of a woman, which in turn also 
depends on age. 
 
2.4 Literature Review 
2.4.1 Operations Research and Health Care 
Mathematical models are powerful tools that solve problems without meddling 
with the real-world system, which is often a requirement for healthcare problems as 
indicated in Section 2.2.  Operations Research (OR), the discipline which uses 
mathematical modeling along with other mathematical methods to find the best solutions 
for complex systems, has been used in healthcare for over 40 years (Brailsford, 2007).  
Simulation is the most commonly used OR approach in health care because it can handle 
the stochastic nature of healthcare systems and the high degree of complexity that 
characterizes them, whether modeling diseases or health care facilities such as hospitals or 
emergency rooms (Brailsford, 2007).  Among simulation methods, Discrete-event 
Simulation (DES) is the most commonly used approach in health care in OR studies.  This 
is because DES is the most flexible simulation method in which virtually anything can be 
simulated and allows modeling at the individual (patient) level and can assign attributes to 
the individuals such as age, gender, blood type, etc. to determine their flow through the 
model (Brennan et al. 2006).  Furthermore, DES software packages allow the user to add 
animation to the model, which can serve as a means of communication with non-numerate 
healthcare professionals.  Other simulation methods that are used in healthcare models are 
Decision Trees, Monte Carlo Simulation, and System Dynamics (Brennan et al. 2006).  
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 From an application point of view, the majority of healthcare models fall into two 
major categories.  The first category is operational models that deal with healthcare units 
such as hospitals or emergency rooms.  Such models are concerned with capacity planning, 
resource allocation, and process redesign of the healthcare unit in question (Brailsford, 
2007).  Operational models are classical OR applications which use DES methods and are 
the most prevalent type of healthcare OR studies found in the literature (Brailsford, 2007).  
One example of such a model is the Griffiths et al. (2005) study where an intensive care 
unit was modeled with DES.  The intensive care unit in question had a flexible number of 
beds by bringing additional beds from other parts of the hospital based on demand.  One 
requirement of the intensive care unit however, was to maintain at least a one-to-one ratio 
of nurses to patients, so supplementary nurses had to be recruited at high demand periods.  
Since supplementary nurses are an expensive recourse, the goal of the model was to 
determine the required number of supplementary nurses per shift that met the unit’s 
requirements while minimizing the overall nursing staff costs.  
The second category is called disease modeling and it models biological processes 
(usually some disease progression) of the human body.  Such models are often used to 
study clinical effectiveness and cost-effectiveness of clinical interventions such as 
screening and vaccination as means for disease prevention.  One such example is the 
model in the Tafazzoli et al. (2005) study where a screening structure was added to an 
existing DES model of the natural history of colorectal cancer to perform a cost-
effectiveness analysis on the latest colorectal cancer screening strategies recommended by 
the American Gastroenterological Association.  Many such cost-effectiveness analyses 
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exist, but virtually all of them compare a limited number of predetermined strategies, 
which is an insufficient approach to determine the best timing of the interventions in order 
to maximize their health benefits.  At best, some studies consider the timing of the 
interventions implicitly, by studying if a particular clinical intervention should be 
performed in some age group.  One such example concerns screening mammography for 
breast cancer. Whereas mammography is recommended and considered cost-effective for 
women aged 50 to 70 years of age, the cost-effectiveness of adjacent age groups is a matter 
of debate.  The Kerlikowske et al. (1999) study considered the cost-effectiveness of 
continuing screening mammography for the age group of 70 to 79.  Although this study 
does consider the issue of when the intervention should be performed it does so implicitly 
by considering an age group and by only considering a small number of predetermined 
screening strategies on that age group, which is still insufficient to determine the best 
timing of the interventions to maximize the health benefits of the screenings.  
  A notable exception with respect to properly timing the clinical interventions is the 
Faissol et al. (2007) study which explicitly considers the proper timing of testing and 
treatments for Hepatitis C through optimization.  The study optimizes the timing of the 
screenings by using a special case of a Markov Decision Process (MDP) called Partially 
Observable MDP, where the dynamics of the model are determined by a MDP but 
information on whether someone has the disease can only be obtained from testing.  This 
thesis takes the same approach of properly timing the screenings through optimization for 
the case of cervical cancer but with a different modeling approach.  This thesis uses 
advances made in combining simulation with optimization to perform optimization on a 
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DES model of the natural history cervical cancer to determine the best timing of the 
screenings.  This will be discussed in detail in the remaining sections of this chapter, but 
first a literature review is performed to indicate how mathematical models have been 
successfully applied to study the natural history and clinical interventions for cervical 
cancer.  
 
2.4.2 Cervical Cancer Mathematical Model Studies  
 An accurate natural history of the cervical carcinogenesis is the backbone of any 
mathematical model that tries to assess the efficacy of an existing or a hypothetical cervical 
cancer screening strategy.  Due to the large, systematic literature review needed to obtain 
the best available information about the parameters that determine the natural history of the 
disease, some studies focused solely on constructing a model that accurately portrays this 
process.  For example, Myers et al. (2000) constructed a nineteen-state non-stationary 
Markov model of a cohort of women from ages 15 to 85 primarily for the development of 
an accurate history of natural carcinogenesis.  They conducted sensitivity analysis by 
varying the parameters of the model to evaluate the effects of the changes on CIN I-III 
prevalence and cervical cancer incidence.  A key conclusion from this analysis is that 
cancer incidence is most sensitive to the incidence of HPV and the probability of 
progression of CIN III to cancer. 
 Due to the recent understanding that oncogenic HPV strains cause cervical cancer 
as well as the development of HPV-16/18 vaccines, some studies focused on analyzing the 
type-specific natural history of HPV and the projected effects of such a vaccine.  Goldie et 
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al. (2003) constructed a Markov model that further partitions the HPV types to analyze the 
impact of such a vaccine.  The HPV types were partitioned into non-oncogenic HPV, 
oncogenic 16/18 HPV, and oncogenic non-16/18 HPV, and they conducted a systematic 
literature review to obtain the appropriate age-specific progression and regression 
parameters for the specific HPV types.  The study concluded that a 16/18 vaccine that is 
98% effective is associated with an approximately equivalent reduction in 16/1-associated 
cancer and a 51% overall cancer reduction.  Kohli et al. (2007) also tried to estimate the 
long-term impact of a 16/18 HPV vaccine in the in the context of the United Kingdom. In 
their study, they also incorporated the fact that vaccination offers partial protection against 
oncogenic types HPV 31 and 45.  Their model predicted that the vaccine would result to a 
66% reduction in precancerous lesions and a 76% reduction in both cervical cancer 
incidence and death.  Neither model has evaluated however the beneficial effects of HPV 
vaccination due to herd immunity.  
 Ever since the wide application of organized screenings programs, the incidence 
and mortality of cervical cancer has reduced dramatically in developed countries.  But in 
less-developed countries, cervical cancer is still a leading cause of cancer death in women, 
with 80% of cervical cancers worldwide occurring there (Mandelblatt et al. 2002).  This is 
why some studies have focused on considering alternative cost-effective screening 
strategies for less-developed countries taking into consideration the limited recourses 
available.  Goldie et al. (2001) constructed one such a model for South Africa.  Due to 
reduced recourses and compliance levels in low-recourse settings, the study concluded that 
HPV-DNA or visual inspection screening strategies that eliminate multiple visits can offer 
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cost-effective alternatives to cytology-based (Pap smear) screening.  In another similar 
study that considered the cost-effectiveness of cervical cancer in five developing countries, 
Goldie et al. (2005) concluded that screening women once in their lifetime with visual 
inspection, the lifetime risk of cervical cancer reduced by 25-36%.  The study also 
concluded that the relative lifetime risk reduced an additional 40% with two screenings at 
35 and 40 years of age.  
 Although cervical cancer incidence and mortality have greatly reduced in places 
where organized screening strategies are present, the optimal use of recourses to achieve 
the best possible results is always desirable.  Several papers focused on comparing 
alternative screening strategies in settings where organized screening exists by considering 
alternative screening methods, intervals, and starting and ending ages.  Siebert et al. (2006) 
constructed such a model for Germany in the German health care context.  They developed 
a non-stationary Markov model that depicts the natural history of cervical carcinogenesis 
in Germany.  They considered the cancer incidence, cancer death, and life years saved 
(LYS) if the screening interval is varied from 1 year to 2, 3, or 5 years when starting 
screening at age 20 and stopping at 85.  They concluded that the most cost effective 
screening strategy was every two years since compared with screening every year, the 
reduction in cancer incidence only improved from 2,851 to 2,994 per 100,000 and the 
reduction in cancer death only dropped from 1,000 to 981 per 100,000.  
 Mandelblatt et al. (2002) also considered screening strategies in places with 
organized screening strategies.  They developed a C++ program of a seventeen-state 
Markov model to estimate the expected costs and expected quality-adjusted life years 
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(QALY) gained associated with 18 different screening strategies.  The strategies were 
compared by considering three possible ages to end screening (65, 75, and until death), 
three possible screening strategies (Pap smear, HPV DNA testing, Pap smear and HPV 
DNA testing), and two possible screening intervals (every two and every three years).  
They concluded that screening every two years until 75 with combined HPV and Pap 
smear testing compared to stopping screening until death captured 97.8% of the health 
benefits.  Therefore, considering different age limits associated with screening is a cost-
effective option to maintain the benefits while reducing the costs of screening strategies.  
 
2.5 The Need for Optimization and Thesis Objective 
 In all of the studies where screening strategies were considered, however, only a 
limited number of either de facto or predetermined strategies were considered.  Even in the 
case of the Mandelblatt et al. (2002) study that considered 42 different scenarios, these 42 
scenarios are a very small number of all possible scenarios that could be considered.  In 
fact, screening scenarios with good potential exist if the fact that cervical intraepithelial 
neoplasia (CIN) and cervical cancer risks are age-dependent is considered.  This implies 
that varying the screening intervals, by setting smaller screening intervals at higher-risk 
ages and larger screening intervals at lower-risk ages would provide more cost-effective 
strategies.  Considering all possible combinations of varying screening intervals, with all 
possible starting and ending screening ages is immensely computationally intensive.  Even 
if many cases were eliminated through the understanding of the natural history of cervical 
carcinogenesis, the problem would not be sufficiently reduced so that all remaining 
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alternatives could be considered.  In such cases, where the number of alternative scenarios 
is large, the appropriate method to find the best alternative is with the use of optimization.  
 Optimization algorithms can find the most effective screening strategies in a 
realistic time frame, since they intelligently search alternative solutions within the space of 
all possible solutions.  Even though optimization analysis is a different approach towards 
decision-making from cost-effectiveness analysis, optimization can be used to construct an 
efficiency curve first and then perform cost-effectiveness analysis as described in Section 
2.1.  The construction of the efficiency curve can be achieved through a method called 
repeated optimization; an approach for solving multi-objective optimization models.  
Multi-objective models are models where there are two or more objectives which conflict 
with each other and some tradeoff between them needs to be made.  Models for cervical 
cancer screening strategies are multi-objective since when evaluating alternative screening 
strategies there are two competing objectives; keeping costs that arise from screening, 
diagnosis, and treatment at a minimum while maximizing health benefits such as reduction 
in cancer incidences and cancer deaths.  The two objectives conflict with each other since 
more expensive screening strategies can provide higher levels of health benefits. 
  With repeated optimization, an efficiency curve is constructed by setting to varied 
levels (values) all but one objective, which is then treated as a single objective to be 
optimized.  In the current situation there are only two objectives, so the efficiency curve is 
constructed by setting costs at various levels and then optimizing with respect to 
maximizing the health benefits.  Specifying various cost levels directly on cervical cancer 
screening strategies is not practical, but the number of lifetime screenings available per 
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woman correlates with costs and is easy to vary.  Health benefits can be defined in more 
than one ways; it can be cancer incidences, cancer deaths, or the life years saved in the 
screened population.  Which definition for health benefits is the most appropriate is 
subjective, so in this study all three definitions will be considered and the tradeoffs 
between them will be analyzed.  So, by specifying how many lifetime screenings are 
available per woman (e.g., from 1 to 30) and repeatedly optimizing with respect to 
maximizing the health benefits, the resulting solutions are screening strategies comprised 
by a set of ages when screening occurs that offer the best health benefits possible for each 
given number of lifetime screenings available.  All optimal solutions together comprise the 
constructed efficiency curve.  Note that these solutions also define the optimal starting and 
ending screening ages, which are determined from the smallest and largest ages provided 
by the optimal solutions.  
 The importance of the ages at which screenings are performed has been noted in the 
literature.  For example, Mandelblatt et al. (2002) noticed that stopping screening at 75 
instead of screening until death captured 97.8% of the health benefits.  Goldie et al. (2005) 
predicted that screening women once in their lifetime at age 35 can result in a reduction of 
cervical cancer of 25-36%.  However, the full potential of properly timing screenings, 
which can be reached through optimization, was never taken advantage of since those 
models only considered small numbers of predetermined screening strategies.  
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2.6 Simulation Optimization 
Since the natural history of cervical carcinogenesis is too complex to be modeled 
analytically due to the fact that it is a non-stationary Markov Process (and due to additional 
reasons that will be mentioned in Chapter 3), in this study it is modeled as a discrete event 
simulation model.  Hence, in order to optimize this model, simulation optimization needs 
to be considered.  Simply stated, simulation optimization is any optimization problem 
where the objective function(s) and/or at least one of its constraints are evaluated through 
computer simulation.  As a result, these functions are only implicit, stochastic functions of 
decision variables in the system (Azavidar 1999).  In other words, these functions do not 
have analytical expressions and are estimated through multiple simulation replications at 
specific values of the decision variables.  This makes simulation optimization more 
computationally expensive compared to other types of optimization, but short of this, it is a 
very powerful tool as it allows optimization of complex models that would otherwise not 
be feasible.  Also, simulation models have little to no compromise to their validity (which 
is the degree at which the model and inferences made through the model hold for the real 
system), a compromise which often has to be made when systems are modeled 
analytically.  Also, the complexity of the system being modeled has little to no effect to the 
performance of the optimization process.  
The most common formulation of simulation optimization problems is the 
maximization or minimization of the expected value of the objective function of the 
system.  The general mathematical formulation of simulation optimization problems is:  
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where z is a random vector representing several responses of the simulation model for a 
given value of the decision variable vector X.  f(X) is the unknown expected value that can 
only be estimated by repeated observations of z(X).   P is a vector of stochastic constraints 
which have at most a probability value α to be violated and h is a vector of deterministic 
constraints in the decision variables (Azavidar 1999).  
             Methods used in simulation optimization vary according to the nature of the 
optimization model.  The optimization problem in this study is discrete with a finite but 
combinatorially large feasible space, so the most appropriate methods are metaheuristics 
(Sigurdur and Jumi 2002).  Metaheuristics for the most part use the same local 
improvement principles as other optimization methods to intelligently search the feasible 
solution space, but they do not explicitly use derivatives so no equation of the objective 
function in necessary.  Another key feature of metaheuristic algorithms is that in addition 
to local improvement procedures, they include higher level procedures that allow them to 
escape from local optima and perform a more robust and complete search of the feasible 
region.  Common metaheuristics used in simulation optimization are Tabu Search, 
Simulated Annealing, and Scatter Search.  Metaheuristics cannot guarantee the optimal 
solution, but well-designed ones provide solutions that are at least nearly optimal; a 
limitation which has limited relevance in practice (Sigurdur and Jumi 2002).  To point out 
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this distinction however, the best solution found from a metaheuristic search is sometimes 
called a heuristic optimum. 
                For difficult optimization problems, such as the one in this study, metaheuristics 
are more robust and faster than more conventional optimization algorithms.  Also, due to 
their ability to escape from local optimal and perform a more robust and complete search 
of the feasible region, not only they have a greater chance of reaching the global optimum, 
they also generate multiple alternative solutions while focused on finding the optimal 
solution; something that is very useful in practice (Sigurdur and Jumi 2002).  In fact, all 
these advantages of metaheuristics have made them the dominant methods used in practice 
and in commercial simulation optimization packages regardless of the nature of the 
optimization model that needs to be solved (Sigurdur and Jumi 2002).
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CHAPTER 3 The Cervical Cancer Simulation Model 
 
 
This chapter provides a full description of the model that was developed in order to 
perform the analysis recommended in Section 2.5.  First, the general logical structure and 
assumptions of the model are described, along with the parameters used.  Then, the 
verification and validation of the model will be discussed, which ensure that the model 
works as expected.  Finally, the formulation of the optimization models is discussed. 
The goal of this study is to demonstrate how to construct efficiency curves of 
cervical cancer screening strategies through repeated optimization, by maximizing the 
health benefits subject to the number of lifetime screenings available per woman in the 
screened population.  In order to demonstrate this, a set of parameters that describe the 
natural history of cervical carcinogenesis were required to serve as the groundwork on 
which the analysis is performed.  A systematic literature review was performed to identify 
a model with the most clear and complete set of parameters that describe the natural 
history of cervical carcinogenesis.  In addition, a set of model predictions on cervical 
carcinogenesis in the absence of screening was desirable, as they would allow cross-model 
validation and model calibration.  Examples of such predictions are: lifetime risk of 
developing cancer, age of cancer incidence peak, and prevalence of CIN I-III by age.  The 
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most appropriate model available was developed by Siebert et al. (2006) which was 
designed to describe the natural history of cervical carcinogenesis in Germany.  The 
natural history of cervical carcinogenesis is very similar among Western European 
countries and the United States (Siebert et al. 2006).  Therefore, the natural history of 
cervical carcinogenesis in the Siebert et al. (2006) model is an appropriate template to 
demonstrate the advantages of optimizing the effects of cervical cancer screenings by 
determining the best combination of years to perform them. 
  
3.1 General Logical Structure, Assumptions, and Parameters of the Model 
 The cervical cancer simulation model is comprised by two sub-models.  The first 
sub-model simulates the natural history of cervical carcinogenesis and the second 
simulates screening and treatment imposed by clinical interventions.  Sections 3.1.1 and 
3.1.2 provide a description of the logical structure, assumptions, and parameters used for 
the two sub-models.  
 
3.1.1 Assumptions and Logical Structure of the Natural History Sub-model 
 The general structure of the natural history sub-model is a sixteen-state Markov 
process that simulates the natural history of cervical carcinogenesis, as described in 
Section 1.5, over a hypothetical cohort of 100,000 women from ages 15 to 85 years old.  
Figure 3 provides a graphical representation of the Markov process where the squares 
represent the health states and the arrows represent the possible transitions between the 
states over a Markov cycle of one year.  Each possible transition in the model has a set of 
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age-specific transition probabilities, which can be thought of as a one-dimensional array 
indexed over age as described in Section 2.4. 
 
Figure 3: Graphical Representation of the Markov Process for the Natural History of 
Cervical Carcinogenesis.  
 
The sixteen states of the model, along with their possible transitions are as follows: 
1. Well: There are no cell changes on the skin of the cervix.  
From this state, a woman can remain in the same state, progress to CIN I, move to benign 
hysterectomy, or die from some cause other than cervical cancer. 
2. CIN I: Mild cell changes on the skin of the cervix.  
From this state, a woman can remain in the same state, regress to well, progress to CIN II, 
move to benign hysterectomy, or die from some cause other than cervical cancer.  
3. CIN II: Moderate cell changes on the skin of the cervix.  
From this state, a woman can remain in the same state, regress to well, progress to CIN III, 
move to benign hysterectomy, or die from some cause other than cervical cancer.  
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4. CIN III: Severe cell changes on the skin of the cervix.  
From this state, a woman can remain in the same state, regress to well, progress to FIGO I 
cervical cancer, move to benign hysterectomy, or die from some cause other than cervical 
cancer. 
5 – 8. Undiagnosed (Undiag.) FIGO I – IV: Cervical cancer that has not been detected 
through symptoms or screening.  
From these states, a woman can remain on the same stage of cancer, progress to the next 
stage, develop symptoms and move to known cancer of the same level, or die from some 
cause other than cervical cancer.  At undetected FIGO IV stage of cervical cancer, the 
woman can move to death from cervical cancer.  At cancer states, regression to previous 
stages of cervical carcinogenesis is not possible.  
9 – 12. Diagnosed (Diag.) FIGO I – IV: Cancer that has been detected through symptoms 
or screening.  
At these states a woman is considered to be treated for cervical cancer according to the 
stage of the cancer, as described in Section 1.8.  If treatment is successful, and no 
reoccurrence of cancer is seen for a period of five years the woman moves to the cancer 
survivor state.  Otherwise, she moves to the cancer death state.  During these five years a 
woman can also die from some cause other than cervical cancer.   
13. Benign Hysterectomy: Hysterectomy performed for reasons other than cervical cancer.  
If hysterectomy is performed for some reason other than cervical cancer, there are no risks 
for developing precancerous lesions and hence cervical cancer.  So from this state a 
woman can either stay at the same state, or die from some cause other than cervical cancer.  
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14. Cancer Survivor: Cervical cancer survivor five years after cervical cancer diagnosis 
and treatment.  
Women at this state, can remain in the same state, or die from some cause other than 
cervical cancer.  This is actually a limitation of the model since there is a risk of cervical 
carcinogenesis after successful treatment, but this is how all studies found model cervical 
carcinogenesis including the Siebert et al. (2006) model.  This however, has negligible 
affect on the results of this thesis which are the best ages screenings should occur.  This is 
because the age specific risks of CIN (which are the primary factor that determines the best 
ages screening should occur, as it will be indicated in Chapter 4) are negligibly affected by 
this limitation.  
15. Cancer Death: Death due to cervical cancer.  
Women in this state stay in this state.  
In the developed model, while in this state, women still move on with their lives as if they 
did not die cancer and may “die” from some cause other than cervical cancer, in order to 
record the number of years each woman would have had, had she not died from cervical 
cancer.  These recorded “life years lost” will be used as a means to optimize the screening 
strategies with respect to life years saved in the screened population.  This is discussed in 
more detailed in Section 3.3 where the formulations of the optimization models are 
discussed.  
16. All Cause Death: Death due to causes other than cervical cancer.  
Women at this state remain at this state. 
In the developed model, women are disposed from the simulation at this state. 
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  Note that benign hysterectomy and all cause death transitions probabilities are 
independent transition probabilities from all the other ones.  All other transition 
probabilities describe the progression of cervical carcinogenesis over time for a cohort of 
women.  Benign hysterectomy and all cause death transition probabilities, however, 
remove women from this progression, since when a woman has a benign hysterectomy or 
dies from some other cause, there is no longer an issue of cervical carcinogenesis.  The 
result of this is that the model is not a pure Markov process.  To indicate that transition 
probabilities for benign hysterectomy and all cause death are independent from the rest 
transition probabilities which describe the progression cervical carcinogenesis, their arrows 
in Figure 3 are colored blue, as opposed to black.  
The fact that the model is not a pure Markov process does not affect the analysis 
that can be achieved with this model because it is modeled as a simulation, but it does have 
some implications to the structure and the parameters of the model.  In Section 2.3 it was 
mentioned that since a Markov process must make a transition into some state over one 
Markov cycle, then the transition probabilities ijp for each state i to some state j must 
satisfy the property 1
1
=∑
=
s
j
ijp , si ,...,1=  are the states of the process.  Since the transition 
probabilities for benign hysterectomy and all cause death are independent probabilities, 
their transition probabilities should not be included in this sum.  With respect to the 
structure of the process, the implication is that at each state the model needs to first check 
if a woman has been removed from the progression of cervical carcinogenesis either 
through benign hysterectomy or all cause death.  Provided that she has not, then the 
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transition probabilities for all other states can be considered.  For example, when a woman 
is at the CIN I state, the model first needs to check if the woman has died from some cause 
other than cervical cancer over that Markov cycle.  Provided that she has not, then the 
model needs to check if she has had benign hysterectomy over that Markov cycle.  If 
neither of the two has occurred, then the model can apply the transition probabilities that 
describe the progression of cervical carcinogenesis.  For states after cancer incidence, since 
benign hysterectomy is no longer a possibility, the model must only check if the woman 
has died from some cause other than cervical cancer. 
Tables 1 through 3 summarize the parameters used in the natural history sub-model 
as taken from Siebert et al. (2006):  The annual transition probabilities that describe the 
natural history of cervical carcinogenesis, the five-year survival rates for cancer after 
detection and treatment, and the annual transition probabilities that remove women from 
the cervical carcinogenesis process, namely the annual hysterectomy and annual all cause 
death rates.  The Siebert et al. (2006) model did not include the all cause death rates used, 
so US 2003 death rates, taken from the Centers for Disease Control and Prevention 
website, were used instead.  Due to the fact that all cause death rates are transition 
probabilities that remove women from the natural history of cervical carcinogenesis 
process rather than describing it, using the US 2003 death rates would have no impact to 
the validity of the model.  
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Table 1: Cervical Carcinogenesis Natural History Transition Probabilities 
Origin State Destination State Age Annual Probability  
Well CIN I 15-85 0.0017 - 0.0521  
CIN I CIN II 15-34 0.0173  
  35-85 0.0595  
CIN II CIN III 15-85 0.0567  
CIN I Well 15-34 0.1027  
  35-85 0.0645  
CIN II Well 15-34 0.1027  
  35-85 0.0645  
CIN III Well 15-85 0.0567  
CIN III Undiag. FIGO I  15-85 0.0410  
Undiag. FIGO I Undiag.FIGO II 15-85 0.2015  
Undiag. FIGO II Undiag. FIGO III 15-85 0.2592  
Undiag.FIGO III Undiag. FIGO IV 15-85 0.3624  
Undiag. FIGO I Diag. FIGO I 15-85 0.1098  
Undiag. FIGO II Diag. FIGO II  15-85 0.2150  
Undiag. FIGO III Diag. FIGO III 15-85 0.6120  
Undiag. FIGO IV Diag. FIGO IV 15-85 0.9000  
     
Table 2: Five-year Survival Rates for Cervical Cancer after Diagnosis and Treatment 
  Cancer State 5-year survival rate  
  FIGO I 0.943  
  FIGO II 0.736  
  FIGO III 0.594  
  FIGO IV 0.238  
     
Table 3: Transition Probabilities that Remove Women from the Cervical Carcinogenesis  
Progression 
All cause death rates  Benign hysterectomy rates 
Ages Annual Probability Ages Annual Probability 
00 - 09 0.001350  15-35 0 
10 - 14 0.000159  35-39 0.0113 
15 - 20 0.000401  40-44 0.0107 
20 - 24 0.000473  45-49 0.0107 
25 - 34 0.000640  50-85 0.0060 
35 - 44 0.001488    
45 - 54 0.003169    
55 - 64 0.007380    
65 - 74 0.018647    
75 - 85 0.018647    
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3.1.2 Assumptions and Logical Structure of the Screening and Treatment Sub-model 
 In the simulation, when a woman has a Pap smear scheduled, which is determined 
by her age, she is sent from the natural history sub-model to the screening and treatment 
sub-model.  First a Pap smear test is performed.  If the test is negative, the woman is sent 
back to the natural history sub-model to the same state that she was when she left it.  If the 
test result is positive for abnormal cells, women undergo treatment by the methods 
described in Section 1.7.  Table 4 summarizes the Pap smear sensitivity and specificity 
rates.  It is assumed that after a positive Pap smear, a cone biopsy is performed to 
accurately establish the correct classification of the abnormality.  All treatments are 
considered to be 95% effective, which is consistent with effectiveness levels used in other 
studies (e. g., Maxwell et al. 2002, Mandelblatt et al. 2002).  If treatment is successful, the 
woman is sent back to the well state in the natural history sub-model.  If treatment is 
unsuccessful, the woman is returned to the natural history sub-model to the same state that 
she was when she left it.  If the test is positive for cancer, then the woman is sent to the 
appropriate diagnosed FIGO state where she will be treated for cervical cancer according 
to the stage of the cancer, as described in Section 1.8.  
 Compliance levels of women, which describe their willingness to follow up on 
screening and treatment, were considered to be 100%.  This is not a realistic assumption so 
it warrants some explanation.  Since compliance levels in the literature are not age 
dependent, changes in their levels do not affect the best ages screenings should occur.  
Putting lower compliance levels however, would increase the variance of the outputs of the 
simulation which in turn would effect how reliably the optimization would reach the 
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optimum screening ages.  Furthermore, it is desirable to show the potential health benefits 
of the recommended screening policies if followed fully.  Once the recommended 
screening policies are determined, lower compliance levels can be applied for the cost-
effectiveness analysis that reflect the specific population in question.  
  It was also assumed that no surveillance after treatment for abnormal smears was 
performed (where follow up Pap smears are performed to confirm that treatment was 
successful) which is not a realistic assumption in high income settings.  The reason for this 
is because surveillance strategies vary greatly among different populations of interest from 
no surveillance in settings where only a few lifetime screenings are available, to 
surveillances that can last up to two years in populations where large numbers of lifetime 
screenings are available.  Adding surveillance strategies would have negligible affect on 
the optimum screening ages (due to the negligible impact on the age specific risks of CIN) 
especially when the number of lifetime screenings is large where surveillance strategies 
exist.  So, in order to maintain a general pertinence for the model no surveillance strategy 
was added to the model.  Again, once the recommended screening policies are determined, 
population specific surveillance strategies can be considered when cost-effectiveness 
analysis is performed.  
Table 4: Pap smear Sensitivity and Specificity Rates 
State Specificity (%) Sensitivity (%) 
Well  95%  
CIN I   47.1% 
CIN II   71.8% 
CIN III   71.8% 
Undiag. FIGO I - IV  71.8% 
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3.2 Construction, Verification, and Validation of the Model  
3.2.1 The Cervical Cancer Discrete Event Simulation Model 
 A discrete event simulation model was built as described in Section 3.1 using the 
Arena software, version 10.00.00 developed by Rockwell Software, Inc.  A discrete event 
simulation represents a system as a chronological sequence of events that occur in discrete 
points over time.  Each event marks a change in the system.  Figure 4 depicts the cervical 
cancer simulation model in Arena.  
As can be seen in Figure 5, there are three major parts to the visible part of the 
simulation.  The first part is the natural history sub-model, which deliberately looks very 
similar to the graphical representation of the Markov process depicted in Figure 4.  While 
the simulation is running, the woman that is currently going through her lifespan in the 
simulation can be seen moving through the different health states to provide an image of 
her current status with respect to cervical cancer.  The second visible part of the model is 
the screening and treatment sub-model.  When a screening is scheduled at a specific age, 
the woman currently in the simulation is routed from the natural history sub-model to the 
screening and treatment sub-model.  After she goes through screening and treatment, she is 
sent back to the appropriate state in the natural history sub-model.  The third and final 
visible part of the simulation is titled “Current Individual” and is purely for visualization 
purposes.  It provides an account of the current status of the woman currently in the 
simulation (i.e. current age, current health status, age for the next scheduled screening, and 
the number of the next screening).  
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Figure 4: The Cervical Cancer Simulation Model in Arena 
3.2.2 Model Verification  
Verification is the process of ensuring that the logical structure of the developed 
model is as it was intended (i.e. as described in Section 3.1).  The main technique that was 
used was following the women step by step as they moved through the simulation to make 
sure that the logic they followed was correct.  At the same time, the all the parameters in 
the simulation were kept track of to ensure that the simulation was reading the correct 
parameter values at each point of the simulation.  In addition, alternative values to the 
parameters were used to create more predictable conditions and confirm that the simulation 
was behaving according to the parameter values used.   
 
3.2.3 Model Calibration and Validation 
Model validation is the process of ensuring that the developed model behaves the 
same way as the real system that is being simulated.  In the particular case of this study, 
  47 
since the natural history parameters used were from the Siebert et al. (2006) model, cross-
model validation had to be performed to ensure that the predictions of the developed model 
in the absence of screening agreed with the predictions of the Siebert et al. (2006) model.  
In addition, in the parameters provided in the Siebert et al. (2006) model, the set of 
parameters that describe the transition probabilities from Well to CIN I were not explicitly 
defined for different ages.  It was only known that the transition probabilities ranged from 
0.0017 - 0.0521 for ages 15 to 85, as it can be seen in Table 1.  Therefore, calibration was 
performed on these parameters, which is the process of changing values of model input 
parameters within a plausible range, in an attempt to match model output with an observed 
set of data. 
The developed model was calibrated and validated based on all the Siebert et al. 
(2006) model predictions in the absence of screening.  As mentioned in the introduction of 
Chapter 3, one of the advantages of the Siebert et al. (2006) model was that it provided 
many predictions of the model in the absence of screening, which allowed a detailed 
calibration to be performed.  Figure 5 and Table 3 summarize all the provided predictions.  
Figure 6 depicts the age-specific CIN I - III prevalence in the population, which is 
particularly useful in calibrating the transition probabilities from Well to CIN I.  Table 3 
summarizes predictions that regard cervical carcinogenesis on the entire population such as 
peak ages for CIN I- III prevalence and cancer incidence, lifetime risk of cervical cancer, 
and the distribution of symptoms development for all the FIGO states.  
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Figure 5: Age-specific CIN Prevalence from the Siebert et al. (2006) Model 
 
 In order to calibrate the Well to CIN I transition probabilities, the age-specific 
prevalence of CIN I of Figure 5, were extracted for all ages.  Then calibration was 
performed through optimization, by determining the Well to CIN I transition probabilities 
that minimize the deviation of the age-specific prevalence rates provided by the model and 
the ones provided from Figure 5.  The values of the transition probabilities for each age 
were restricted between 0.0017 - 0.0521 as reported in Siebert et al. (2006).  The 
optimization model used was 
85
15
min
i
i i
i
CINI CINIOBS
=
=
−∑  
Subject to: 
    0521.00017.0 ≤≤ iWellToCINI ,  i=15, …, 85 
where   
iCINI  is the CIN I prevalence at age i from the Siebert et al (2006) model,  
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iCINIOBS is the CIN I prevalence at age i observed in the developed model, and  
iWellToCINI  is the transition probabilities from Well to CIN I which were determined by 
the optimization.  
After the Well to CIN I transition probabilities were calibrated, cross model 
validation was performed, which is summarized in Table 5 and Figure 6.  Figure 6 depicts 
the age-specific prevalence rates of CIN I – III and total CIN as predicted by the developed 
model, along with the CIN I prevalence as predicted by the Siebert et al. (2006) model.  It 
can be seen from Figure 6 that the CIN I prevalence rates from the developed model and 
the Siebert et al. (2006) model match exactly.  Also the CIN II, CIN III, and CIN Total 
prevalence rates from the developed model match with the prevalence rates of the Siebert 
et al. (2006) model depicted in Figure 5.  
Table 5 summarizes all other cross-validation predictions between the developed 
model and the Siebert et al (2006) model.  For the peak ages of CIN II and CIN II there are 
ranges of ages instead of one age because those ages exhibited the same prevalence rates at 
three decimal points.  Peak age for cervical cancer incidence also has a range of ages 
because those ages have the same cancer incidence within plus or minus one cancer per 
100,000.  The discrepancy in cervical cancer deaths is due to the fact that the developed 
model, unlike the Siebert et al. (2006) model, incorporated that during the five years after 
cancer detection and treatment, at which the five year survival rates are imposed, women 
could also die from other causes.  The “percentage of symptoms developed” predict what 
percentage of cancers developed symptoms at each cancer state in the absence of 
screening.  Figure 7 depicts age-specific cancer incidence, cancer symptoms incidence and 
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cancer death incidence as predicted from the developed model; the Siebert et al. (2006) 
model did not provide figures for these predictions to allow comparison. 
 
Table 5: Model Prediction and Cross-model Validation Values 
Model Predictions Siebert et al. Developed model  
Peak age (years) of CIN I  25 25 
Peak age (years) of CIN II  38 32-39 
Peak age (years) of CIN III  48 43-47 
Peak age (years) of cervical cancer incidence 51 40-47 
Peak incidence of cervical cancer (per 100,000) 84 95% C.I. (75.2, 82.4) 
Cervical cancer incidence (per 100,000)  3032  95% C. I. (3018, 3054)  
Cervical cancer death (per 100,000)  1004  95% C. I. (817, 837)  
Percentage of symptoms developed at FIGO I  38.8% 36.3% 
Percentage of symptoms developed at FIGO II 31.6% 29.5% 
Percentage of symptoms developed at FIGO III 24.1% 22.1% 
Percentage of symptoms developed at FIGO IV 5.45% 5.1% 
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Figure 7: Cervical Cancer, Cervical Cancer Symptoms and Cervical Cancer Death 
Incidences as Predicted from the Developed Model 
 
3.3 Formulation of the Optimization Model  
Once a model has been verified and validated, it can be used to perform various 
analyses with.  The goal of this study is to show the advantages of constructing the 
efficiency curve to be used for cost-effectiveness analysis, through repeated optimization 
on the health benefits subject to the number of lifetime screenings available.  So the first 
step is to formulate the appropriate optimization model.  This means determining the 
appropriate objective to be maximized or minimized, a set of control variables that can be 
changed during the optimization process, and a set of constraints on the control variables 
that may be needed to enforce certain requirements. 
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The objective function quantifies the measure of performance that alternative 
screening strategies are evaluated with, which in this case are the expected (average) health 
benefits that result from the screening strategies.  Health benefits from cervical cancer 
screening can be defined in three ways; the expected reduction in cancer incidences, the 
expected reduction of cancer deaths, and the expected life years saved in the screened 
population.  Which measure of health benefits is the most appropriate is subjective, so 
optimizations are performed for all three measures and the tradeoffs between them are 
analyzed.  Minimizing the expected cancer incidences and the expected cancer deaths is 
straightforward with the discrete event simulation model that was constructed because it 
records the cancer incidences and cancer deaths as they occur in the simulation.  
Evaluating alternative screening strategies with respect to the life years saved 
(LYS) in the screened population is an important alternative measure of the health benefits.  
This is because unlike cancer incidence and cancer deaths, LYS distinguishes if a cancer 
incidence or death was averted from a woman of young age (and therefore saving many 
life years) or from a woman of old age (and therefore saving just a few years of life).  
Maximizing with respect to the expected LYS is not as straight forward however because 
less than 1% of the screened population is expected to die from cervical cancer in the 
absence of screening, so less that 1% receives improvement with respect to life years.  This 
improvement gets diluted in the life years of the remaining population which results to 
very small overall improvement in life years due to screenings.  These small improvements 
along with the stochastic nature of the model would make it infeasible for the optimization 
algorithm to work properly by maximizing the expected life years of the screened 
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population.  This is because the optimization algorithm would not be able to distinguish if 
an increase in the expected life years in the population is actual improvement or a result 
from noise due to the stochastic nature of the model.  
To overcome this difficulty, the LYS in the screened population have to be isolated 
somehow, so that they can be measured.  To achieve this, in the discrete event simulation 
model that was developed, when women move to the cancer death state, instead of being 
disposed, they are allowed to move on with their lives as if they did not die from cancer 
and may still “die” from some cause other than cervical cancer.  In this sense, the cancer 
death state behaves like a pseudo-Markov state in the simulation, since women reaching 
this state should have been disposed from simulation as they are when they reach the all 
cause death state.  Letting them stay in the simulation allows the simulation to record the 
number of years each woman would have lived more, had she not died from cervical 
cancer at the age that she did. Minimizing the expected “life years lost” (LYL) is 
equivalent to maximizing the expected LYS from the screened population.  
Control (or decision) variables are variables that can be changed during the 
optimization process with the goal of improving the performance of the system.  In other 
words, they represent the available decisions in order to achieve the objective.  The 
decisions that need to be made are the ages each screening is to be performed.  Based on 
the number of lifetime screenings available, there needs to be an equivalent number of 
variables that represent the ages those screenings are to be performed.  Furthermore, since 
each decision is some age, the decision variables need to be positive integers.  More 
formally the control variables are  
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            i =X the age the i
th screening is to be performed, i = 1… n,  i
+
Ζ∈X ,  
           where n is the number of lifetime screening available.  
The optimization model could have been equivalently modeled as a binary integer model 
by setting binary control variables tY , 85,...,15=t  where 1t =Y  if screening is performed at 
age t, and 0t =Y  otherwise.  This formulation however would not have been as practical to 
apply on the simulation model.  
Constraints are relationships that involve the control variables, and possibly other 
parameters of the model, that enforce certain requirements to be satisfied.  The first 
requirement about the screening ages is that they should be performed during the time 
horizon of consideration of the model.  So each screening age needs to be between 15 and 
85 years of age.  More formally, the first set of constraints is  
8515 ≤≤ iX , ni ,...,1= . 
The second set of constraints enforced in the optimization model is that the first screening 
age needs to be smaller than the second screening age, which needs to be smaller than the 
third screening age, and so on.  More formally,  
11 +≤+ ii XX , 1,...,1 −= ni .  
This set of constraints is not essential for the optimization model to work properly, but it 
does help to greatly reduce the number of solutions being considered.  For example, 
consider three lifetime screenings without the second set of constraints being imposed.  
Then for the optimization algorithm, the solution X1=23, X2=28, X3=32, is different from 
solution X1=28, X2=32, X3=23.  In fact all 3! (= 6) rearrangements of the three ages, which 
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define the same screening strategy, are considered as different solutions from the 
optimization model.  So when n lifetime screenings are available, the second set of 
constraints, reduces the number of solutions to be considered by a factor of n!.   
The formulation of the optimization model is then as follows:  
Min )(Xf = E[Cancer incidences(X)] OR E[Cancer deaths(X)] OR E[Life years lost(X)] 
   Subject to:    8515 ≤≤ iX , ni ,...,1=  
11 +≤+ ii XX , 1,...,1 −= ni  
    +∈ZX i  
where Xi = the age the i
th screening is to be performed,  
           n = the number of lifetime screenings available, and 
           X = (X1, …, Xn) 
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CHAPTER 4 Analysis and Results 
 
 
 This chapter reports and analyzes the results from the simulation optimizations.  
First, an overview of the how the simulation optimizations were performed in Arena is 
provided.  Then, it is shown how the heuristic optimum solutions given by the simulation 
optimizations can be used to provide practical screening strategies that can be used as 
policy recommendations.  Finally, an analysis is performed on those strategies, along with 
a comparison to constant interval screening strategies which have been used in practice and 
considered in the literature. 
 
4.1 Performing the Simulation Optimizations in Arena 
 Arena uses a package called OptQuest from OptTek Systems Inc. to perform 
simulation optimization.  OptQuest intergrades metaheuristics such as Tabu Search, Neural 
Networks, and Scatter Search, into a single composite method that is very robust and is 
geared towards global optimization.  Because metaheuristic algorithms do not explicitly 
use derivatives, if they reach a local optimum, they are not aware of it so they can 
automatically stop the search. Therefore, a stopping criterion needs to be imposed.  
Common stopping criteria used on metaheuristic optimization algorithms are the amount of 
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time the algorithm should run, the number of solutions it should examine, or a certain goal 
value the objective function should reach.  
In order to give the optimization process ample opportunity to reach the global 
optimal solution, it was first set to check a minimum of 1,400 solutions.  If the best 
solution was found on the last 300 solutions checked, it was assumed that further progress 
was still likely, and OptQuest was set to run additional simulations until the last 200 
solutions that were checked did not provide a better solution.  This occurred very few 
times in this study and in no cases did the additional solutions checked provide better 
solutions, indicating that 1,400 solutions were a sufficiently large to allow the optimization 
algorithm to be effective.  The expected value at each solution checked during the 
optimization was estimated through three replications.  Once the search ended, the top 25 
solutions were run 30 replications each to get more accurate expected value for each one.  
Then, the solution with the best expected value was selected and considered the heuristic 
optimum screening strategy.  On an Intel ® Pentium ® D CPU 3.40GHz, 2.00 GB of RAM 
system, the optimization required approximately 35 hours to run the first 1,400 solutions 
and approximately two and a half days to perform the entire optimization process.  
For each of the three objective functions that quantify the health benefits resulting 
from screening strategies (i.e., cancer incidence, cancer death, and life years lost), twenty-
two distinct optimizations were performed, one for each number of lifetime screenings 
available from one to twenty two.  The decision to stop at twenty-two lifetime screenings 
was primarily due to the fact that improvement of the objective functions value from that 
point on was very small with respect to all three definitions of health benefits.  Also, 
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twenty-two screenings is the number of lifetime screenings required by the constant 
interval screening strategy of screening every three years from 20 to 85 years of age.  
Tables 6, 7, and 8 provide a summary of the heuristic optimum solutions with 
respect to cancer incidence, cancer deaths, and life years lost, along with their objective 
function values estimated from thirty replications at each solution.  Before further analysis 
is done on these solutions however, some considerations need to be made.  First of all, 
since this is a simulation model, the values of different solutions cannot be evaluated 
exactly but must be estimated.  Furthermore, from the top 25 solutions provided by each of 
the optimizations it was indicated that many nearby solutions to the heuristic optimum 
solution have objective function values that are not significantly different from (and many 
times equal to) those of the heuristic optimums.  This is an advantage of the higher level 
procedures of metaheuristic algorithms that allow them to escape from local optima and, as 
a result, generate multiple alternative solutions while focused on finding the global 
optimum.  Finally, the optimization model in question is pure integer and is also fairly 
nonlinear (as it was found by looking at neighboring solutions of the heuristic optimum 
solutions), so calculation of a local gradient to identify whether a solution is a local 
optimum does not strictly apply nor it is useful.  Keeping all this in mind, a heuristic 
optimum solution is not as important in itself, but is rather more important in that it 
indicates a small region of the feasible space where solutions exist that have objective 
values that are not significantly different from that of the heuristic optimum.  From this 
point on in the thesis this region will be referred to as the optimality region.  This is 
advantageous from a practical point of view since for each optimization, a pool of 
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available solutions exists rather than just one.  The estimated objective values of the 
heuristic optimum solutions are important in the sense that they provide a heuristic lower 
bound of what is the best that can be achieved with the specific number of lifetime 
screenings available from which alternative solutions can be compared to.  These facts 
about the heuristic optimum solutions can be taken advantage of to construct screening 
strategies that not only are as effective as the heuristic optimum solutions but can also be 
prescribed as practical screening policies. 
 
Table 6: Heuristic Optimum Solutions With Respect to Cancer Incidence 
 
 
 
Table 7: Heuristic Optimum Solutions With Respect to Cancer Deaths 
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Table 8: Heuristic Optimum Solutions With Respect to Life Years Lost 
 
 
4.2 Constructing Practical Screening Strategies from the Heuristic Optimum 
Solutions  
The heuristic optimum solutions from Tables 6, 7, and 8 are very effective, but they 
have one shortcoming compared to the existing, constant interval screening strategies used 
in practice.  They lack a visible pattern and hence are not as practical to prescribe as 
screening policies that can easily be followed, which is an important element for screening 
policies in practice.  Strategies that have a more visible pattern, while maintaining their 
effectiveness, would be more suitable to use as policy recommendations since they are 
simpler to understand and hence are more likely to be upheld by the screened population. 
So, the fact that each heuristic optimum solution in fact indicates an optimality region was 
used to search for smoother, equally effective solutions.  Smoothing the solutions had 
primarily two goals.  The first goal was to provide solutions with constant screening 
intervals as much as possible across different age ranges.  The second goal was to use 
screening ages that had values that were multiples of 2, 5, or 10, since patterns are more 
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easily recognizable with such numbers.  For example, a smoothed screening strategy with 
12 lifetime screenings available could have a screening interval of three years from 22 to 
46 years of age and a screening interval of five years from 50 to 60 years of age.  
The objective value of a candidate solution was considered not to be significantly 
different from that of the heuristic optimum solution if its value estimated from 30 
simulation replications fell within the 95% confidence interval of the heuristic optimum 
solutions, also estimated from 30 simulation replications.  More specifically, since the goal 
was to minimize the three objectives (cancer incidence, cancer death, and life years lost), a 
candidate smoothed solution had to have an objective value no larger than the value of the 
heuristic optimum screening strategy plus the value of its 95% half-width.  Thirty 
replications where considered sufficiently large since the sizes of the resulting half-widths 
were sufficiently small from a practical point of view with respect to all three measures of 
performance.  The sizes of the half-widths at various levels of cancer incidence, cancer 
deaths, and life years lost can be seen in Tables 6, 7, and 8 respectively. 
 A thorough search for smoother screening strategies was performed for all the 
heuristic optimum solutions.  From the search for smoother screening strategies it was 
observed that for cancer incidence and cancer death, solutions deviating more than two 
(sometimes three) years from the ages of the heuristic optimum solutions rarely maintained 
objective function values that where not significantly different from the heuristic optimum.  
So, the optimality regions for the heuristic optimal solutions for cancer incidence and 
cancer deaths had a radius of roughly three years.  The deviation that could be made from 
the ages of the heuristic optimum solutions with respect to life years lost was larger.  The 
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reason for this can be seen by considering screening once in a lifetime.  By screening at 
age 35 versus 33, for example, there is a certain reduction in cancer incidences and cancer 
deaths.  With respect to life years lost however, that difference is scaled down because the 
smaller number of cancer deaths averted by screening at age 33 is balanced out by a larger 
number of years saved per cancer death averted, and the fewer number of life years saved 
per cancer at age 35 is balanced out by a larger number of cancer deaths averted.  As a 
result, the optimality region for the heuristic optimal solutions for life years lost was larger, 
sometimes extending up to five years.   
Within the optimality regions however, not all solutions were not significantly 
different from the heuristic optimum.  The solutions within the optimality regions also had 
to maintain a certain frequency of screening at different age ranges that reflected the risks 
of developing abnormal or cancerous cells at those ages.  The heuristic optimum solution 
with respect to cancer incidence with six lifetime screenings for example was screening at 
ages 24, 29, 33, 39, 47, and 52.  The smoothed solution of screening at ages 25, 30, 35, 40, 
45, and 50 (i.e., screening every five years from ages 25 to 50) maintains a cancer 
incidence that is not significantly different from the heuristic optimum not only because 
the new ages are at most two ages away from the heuristic optimum ones, but also because 
it maintained the frequencies the screenings where performed.  The solution of screening at 
ages 23, 30, 32, 40, 46, and 53 for example, has screening ages deviate one only year from 
the heuristic optimum solution, but it results to significantly higher cancer incidence than 
the heuristic optimum, because screening ages 30 and 32 are too close and they leave a big 
gap from ages 23 to 30 and ages 32 to 40 compared to the heuristic optimum solution.  
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One result that came from searching for smoother solutions was that, even though 
the optimality regions were not very large, there was a great deal of overlap among the 
optimality regions of the three objectives.  This can be also seen by looking at the heuristic 
optimum solutions at Tables 6, 7, and 8.  By looking at the heuristic optimum solutions of 
cancer incidence and cancer death at Tables 6 and 7 for example, it can be seen that the 
solutions are almost identical.  In fact the vast majority of the screening ages are two or 
less years apart, where the cancer death screening ages are on average one year larger than 
the screening ages for cancer incidence.  This indicates that optimality regions of cancer 
incidence and cancer deaths almost completely overlap.  By looking at the heuristic 
optimum solutions of life years saved at Table 8, they are slightly smaller than the 
screening ages of cancer incidence and cancer death but they where still fairly close to 
them, being on average about two to three years smaller that the screening ages for cancer 
incidence.  
As a result, one set of smoothed screening strategies was constructed with objective 
values that were not significantly different from the heuristic optimum objective values 
with respect to all three criteria.  In addition, in most cases any increase of the objective 
values were well within the half-width and in some cases even, solutions were found that 
where slightly better than the heuristic optimum found by the simulation optimizations. 
The only exceptions were four screening strategies (of 4, 6, 15, and 18 lifetime screenings 
available) where life years lost marginally deviated from the 95% confidence intervals of 
the heuristic optimum values.  All attempts however, to create separate smoothed screening 
strategies for those cases resulted to life years lost values so close to the existing strategies 
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(within half the half-width of the 95% confidence interval), that one set of smoothed 
screening strategies was maintained. 
 The reason why the optimality regions of the three objectives overlapped was 
primarily a consequence of the ability to treat precancerous lesions versus cervical cancer, 
and of the natural history of cervical carcinogenesis.  It is easier to see first why the 
optimality regions of cancer incidence and cancer death overlapped.  The effectiveness of a 
solution with respect to cancer incidence is primarily determined by the age-specific risks 
of CIN, particularly CIN II and CIN III.  Overall, good solutions will screen at ages where 
the risks of CIN are high.  By changing the objective from cancer incidence to cancer death 
what is added into consideration besides the age specific risks of CIN, are the age-specific 
risks of asymptomatic cancer which are much smaller in comparison to the risks of CIN. 
Furthermore, the probability of successful treatment of cancer is smaller than the 
probability of successful treatment of precancerous lesions.  These factors, as indicated by 
the simulation optimizations, were significant enough so that optimality regions of cancer 
incidence and cancer death almost completely overlapped.  
 The reason why the optimality regions of life years lost overlapped with the 
optimality regions of cancer incidence and cancer death is because minimizing cancer 
incidence and cancer deaths have a bias towards minimizing life years lost.  This is 
because the risks of CIN (by which the optimized screening strategies with respect to 
cancer incidence and cancer death are primarily determined), are higher at relatively 
younger ages as can be seen in Figure 6, and cancer deaths averted at younger ages save 
more life years.  Furthermore, screenings scheduled at older ages are less likely to be 
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actually performed, since the older a woman is the more likely she is to be dead or to have 
had a benign hysterectomy.  As a result, minimizing cancer incidence and cancer deaths 
have a bias towards minimizing life years lost as well, and as the optimizations indicated, 
this bias along with the larger radius of the optimality regions for life years lost, were 
enough so that the optimality regions for life years lost overlapped with the optimality 
regions of cancer incidence and cancer death.  
Table 9 provides the constructed solutions that are also practical to prescribe as 
screening policy strategies, along with constant interval screening strategies of 2, 3, and 5 
years considered in the literature and used in practice.  Table 10 summarizes their objective 
values with respect to all three objective functions.  The constructed screening strategies 
can prescribe practical screening policies because they are intuitive and easy to follow.  
The constructed screening strategies are easy to follow because they all have a visible 
pattern which makes them easily understood.  More specifically, they can all be partitioned 
into age ranges where the screening interval is constant. For example, the constructed 
screening strategy with 12 lifetime screenings available can easily be expressed as follows:  
“The screening strategy with 12 lifetime screenings available is screening women every 
three years from 22 to 46 years of age and screening them every five years from 50 to 60 
years of age”.  The different age ranges with constant screening intervals are indicated in 
Table 9 through different colors for strategies with nine screenings available and up. 
Furthermore, the constructed screening strategies are intuitive, since the screening intervals 
that they recommend are smaller at ages where the risks of cervical intraepithelial 
neoplasia and cervical cancer are higher and larger at ages where the risks are lower.  
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Table 9: Screening Strategies Constructed by smoothing the Heuristic Optimum 
Solutions, and Constant Interval Screening Strategies 
 
 
Table 10: Objective Values Output of the Screening Strategies Evaluated from 30 
Simulation Replications with Cohorts of 100,000 Women 
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4.3 Evaluating the Performance of the Constructed Screening Strategies  
The screening strategies obtained by smoothing the heuristic optimum solutions are 
very cost-effective; particularly when the number of screenings is small.  For example, 
screening women only once in their lifetime at the age of 35, reduced cancer incidence by 
39% which is also consistent with the results reported by Goldie et al. (2005).  Cancer 
deaths and life years lost were reduced by approximately 45%.  Also, the screening 
strategy with just three lifetime screenings reduced cancer incidence, cancer death and life 
years lost by at least 70%.  Furthermore, the screening strategy with seven lifetime 
screenings reduced cancer incidence, cancer death and life years lost by approximately 
90%.  
 
4.3.1 Comparison with Constant Interval Screening Strategies  
At higher number of lifetime screenings, the effectiveness of the constructed 
screening strategies can also be seen by comparing them to constant interval screening 
strategies, indicated in Table 9 and their corresponding objective values with respect to all 
three objective functions used in the optimizations summarized in Table 10.  A constant 
interval screening strategy can be compared by two screening strategies:  The one that that 
provides about the same health benefits as the constant interval screening strategy and the 
one that uses the same lifetime screenings as the constant interval screening strategy. 
 The first constant interval screening strategy that can be used for comparison is 
screening every five years from 20 to 84 years of age, which requires 14 lifetime 
screenings per woman.  By looking at Table 10, it can be seen that the constructed 
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screening strategy with nine lifetime screenings performs approximately the same with 
respect to cancer incidences (with a cancer incidence of 209 per 100,000 versus 201 per 
100,000 resulting with the constant interval screening strategy) and cancer deaths (with 34 
cancer deaths per 100,000 versus 30 per 100,000 with the constant interval screening 
strategy) and significantly better with respect to life years lost (with 805 life years lost per 
100,000 versus 1,082 per 100,000 with the constant interval screening strategy).  As a 
result the constructed screening strategy with nine lifetime screenings provides about the 
same health benefits as the constant interval screening strategy with 40% fewer scheduled 
screenings.  The constructed screening strategy with 14 lifetime screening performs 
substantially better than the constant interval screening strategy: it results to 100 cancer 
incidences per 100,000 versus 201 cancer incidences per 100,000 resulting from the 
constant interval screening strategy.  Also, the constructed screening strategy with 14 
lifetime screenings results to 12 cancer deaths per 100,000 whereas the constant interval 
screening strategy results to 30 cancer deaths per 100,000.  Furthermore, the constructed 
screening strategy results to 315 life years lost per 100,000 whereas the constant interval 
screening strategy results to 1,082 life years lost per 100,000.  As a result, the constructed 
screening strategy with also 14 scheduled lifetime screenings results to less than half the 
health losses than the constant interval screening strategy with also 14 scheduled lifetime 
screenings.  
 The second constant interval screening strategy that can be used for comparison is 
screening every three years from 20 to 85 years of age, which requires 22 scheduled 
lifetime screening per woman.  By looking at Table 10, it can be seen that the constructed 
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screening strategy with 16 lifetime screenings performs the same with respect to cancer 
incidence (with a cancer incidence of 72 per 100,000) and cancer deaths (with 9 cancer 
deaths per 100,000) and better with respect to life years lost (with 223 life years lost per 
100,000 versus 354 per 100,000 with the constant interval screening strategy).  So, overall, 
the constructed screening strategy with 16 lifetime screenings provides about the same 
health benefits as the constant screening strategy of every three years with about 27% 
fewer scheduled screenings.  The constructed screening strategy with 22 lifetime scheduled 
screening performs substantially better than the constant interval screening strategy that 
also requires 22 scheduled lifetime screenings:  It results to 38 cancer incidences per 
100,000 versus 72 cancer incidences per 100,000 resulting from the constant screening 
strategy.  Also the constructed screening strategy results to 4 cancer deaths per 100,000 
whereas the constant interval screening strategy results to 9 cancer deaths per 100,000.  
Furthermore, the constructed screening strategy results to 95 life years lost per 100,000 
whereas the constant interval screening strategy results to 354 life years lost per 100,000.  
So, overall the constructed screening strategy with 22 scheduled lifetime screenings results 
to fewer than half the health losses than the constant interval screening strategy with also 
22 scheduled lifetime screenings.  It is also worth noting that the constructed screening 
strategy with 22 lifetime screenings results to the same life years lost (with 95 life years 
lost per 100,000) as the constant interval screening strategy of screening every two years 
which required 33 scheduled lifetime screenings.  As a result, the constant interval 
screening strategies are now dominated by the strategies constructed through the heuristic 
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optimum solutions since same levels of cancer incidence, cancer deaths, and life years lost 
can be achieved with fewer lifetime screenings.  
 
4.3.2 Looking at Other Relevant Output of the Screening Strategies  
 Although the screening strategies were evaluated with respect to cancer incidences 
cancer deaths and life years lost, other relevant output were also kept track by the 
simulation model.  Table 11 summarizes some of them which are as follows:  “Screenings 
performed” refers to the actual number of screening performed per 100,000 women for 
each screening strategy, as opposed to the scheduled number of screenings performed per 
100,000 women which equals 100,000 times the lifetime screening available.  “False 
positives” refers to the number of false positives resulting per 100,000 women for each 
screening strategy.  “False positives percentages” refers to the percentage of the actual 
screenings performed that resulted in false positive for each screening strategy.  “Cancers 
Detected by Screening” refers to cancers detected by a Pap smear before the developed 
symptoms.  “Cancers Detected by Screening (%)” refers to the percentage of the total 
cancer incidence that was detected by a Pap smear.  “FIGO I – IV Treated” refer to how 
many women per 100,000 received treatment for cervical cancer at each FIGO state. 
“FIGO Treated Prevented (%)” refers to the percentage of all FIGO treatments prevented 
compared to the total number of FIGO treatments in the absence of screening.  
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Table 11: Additional Output from the Simulation 
 
The number of women treated for cancer per 100,000 women is an important 
measure to keep track of, since treating cancer is not only a painful experience to the 
patients, which also results to a reduction to their quality of life after treatment is 
completed, it is also far more expensive to treat than precancerous lesions.  Costs for 
treating precancerous lesions in the United States range from $800 US to $3,200 US 
according to the stage of the precancerous lesion, whereas costs for cancer treatment range 
from $16,000 US to $45,000 US according to the stage of the cancer (Goldie et al. 2004).  
By looking at “FIGO Treated Prevented (%)” in Table 11 it can be seen that FIGO 
treatments reduce in similar rates as cancer incidences and cancer deaths prevented (which 
can be seen in Table 10), as the number of lifetime screenings increases.   As a result, 
comparing the constructed screening strategies with the constant interval screening 
strategies, provide similar results.  Specifically, the constructed screening strategy with 
nine (sixteen) lifetime screenings results to the same level of cancer treatments reduction 
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as the constant interval screening strategy of screening every five (three) years which 
requires fourteen (twenty-two) lifetime screenings. 
  A measure of performance along the same lines as the number of women treated for 
cancer per 100,000, is the percentage of cancers that are detected from screening before 
they develop symptoms (if symptoms developed at all).  From Table 11 it can be seen that 
as the number of screenings increases, the percentage of cancers that are detected by 
screening also increases. (The actual number of cancers detected by screening decreases, 
because cancer incidence is reduced as the number of lifetime screenings increases).  This 
indicates the benefits of screening not only in detecting abnormal smears and preventing 
cancer, but also in detecting asymptomatic cancer and hence allowing treatment at earlier 
stages of the cancer that would otherwise be performed.  With treatment at earlier cancer 
stages, treatment has higher chances of success, is less costly, and the quality of life of the 
patients after treatment is higher because treatment is less intrusive.  This health benefit of 
screening is also seen in Table 10 where the percentages of cancer deaths prevented, as the 
number of screening increases, are higher than the percentages of cancer incidences 
prevented.  Comparing the screening strategies with the same number of lifetime 
screenings to the constant screening interval strategies it can be seen that the constant 
interval screening strategies have a much higher percentage of cancers detected.  This is 
not an advantage towards the constant interval screening strategies however.  The reason 
why the percentages are higher is because screenings occur with the same frequency at 
early ages (where cancer can be prevented) as in later ages (where cancer is more likely to 
have been developed) and as a result, the constant interval screening strategies prevent 
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fewer cancers at early ages and are more likely to detect them at later ages.  
  False positives are an important issue when it comes to any type of screening in 
medicine, because they cause undue stress and anxiety to the patients, and they also waste 
recourses used in further investigation and possibly treatment.  This is true for cervical 
cancer screening as well.  A Pap smear costs about $35 US (Goldie et al. 2004).  If the 
smear result is positive, it is followed by a colposcopy and biopsy which cost 
approximately $450 US (Goldie et al. 2004).  Although false positives comprise a small 
percentage of the overall number of screenings performed, they result into relatively large 
costs.  By looking at Table 11, it can be seen that there is a small increase in the percentage 
of false positives as the number of lifetime screenings increases.  The reason for this 
increase is because with larger number of lifetime screenings, a smaller proportion of the 
women will have precancerous lesions.  As a result, there will be a larger proportion of 
women without abnormal lesions, and hence the percentage of false positives will increase.  
 Although the percentage of false positives increase is small as the number of 
lifetime screenings increases, the actual number of false positives increases significantly, 
as it can be seen in Table 12.  The cohort of screened women in the simulation remains the 
same.  Hence, it is of interest to also look at the lifetime risks for false positives as the 
number of lifetime screenings increases.  Thus, for each woman in the simulation, the 
number of false positives during her lifetime was recorded in order to provide a probability 
distribution of the number of false positives for women under each screening strategy.  The 
probability mass functions of the probability distributions are summarized in Table 12, 
where each row represents a probability mass function.  Whereas false positives per 
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100,000 women provide a sense of the overall costs resulting from false positives under 
each screening strategy, the probability distribution of lifetime risks for false positives 
provides a sense of the impact of false positives towards women under each screening 
strategy.  For example, the optimized screening strategy with nine lifetime screenings per 
woman, results to approximately 37,300 false positives per 100,000 women, and women 
under this strategy, have about a 68% chance to have no false positives, about 26% chance 
to have one false positive, about 5% chance to have two false positives, and about 0.5% 
chance to have three false positives in their lifetimes. 
The information in Tables 11 and 12 provide a more detailed evaluation of the 
constructed screening strategies that also allows a more complete comparison with the 
constant interval screening strategies.  Recall that the constructed screening strategy with 
nine lifetime screenings provides about the same health benefits compared the constant 
interval screening strategy with screening every five years which requires 14 scheduled 
lifetime screenings.  Note that by looking at the actual screenings performed rather than the 
scheduled screenings, the constructed screening strategy uses only 21.8% fewer screenings 
rather than 40%.   The reason for this is because the constant interval screening strategy 
has more screenings scheduled at older ages when women are less likely to actually receive 
the screening, since the older a woman is the more likely she is to be dead or to have had a 
benign hysterectomy.  Still however, the constructed screening strategy provides the same 
health benefits with substantially fewer screenings.  Also, the constructed screening 
strategy has 24% fewer false positives than the constant interval screening strategy.  
Furthermore, women under the constructed screening strategy have a 68.5% chance to 
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have no false positives versus a 61.4% with the constant interval screening strategy.  
Comparison between the constructed screening strategy with 16 lifetime screenings and the 
constant interval screening strategy of screening every three years, which provide about the 
same health benefits result to similar conclusions.  
 
Table 12: Probability Mass Functions of Lifetime Risks for False Positives 
 
 
 
4.3.3 Overall Conclusions about Constructed Screening Strategies  
 After completing the analysis on the constructed screening strategies, we see how 
we can use heuristic optimum solutions obtained by simulation optimization, to get equally 
effective, smoothed solutions that can serve as practical screening policies.  The 
constructed screening strategies are particularly cost-effective for small numbers of 
lifetime screenings, and are more cost-effective than constant interval screening strategies.  
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In particular, the constructed screening strategies can provide the same health benefits with 
substantially fewer screenings, false positives, and cancer treatments, all of which result to 
a substantial reduction in costs and discomfort to the screened population. 
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CHAPTER 5 Considerations and Projections of Properly Timed 
Screening Strategies in a Post-vaccination Era 
 
           
This chapter performs an analysis on the impact of HPV 16/18 vaccination on 
cervical carcinogenesis, cervical screening, and the heuristic optimum screening strategies 
that result from simulation optimizations, as the duration of sustained vaccine immunity 
increases.  The analysis was performed by creating 40 screening scenarios with varying 
durations of sustained vaccine immunity and different number of lifetime screenings 
available, which were used to draw general conclusions.   
In recent years there has been significant progress in the understanding of the 
natural history of cervical carcinogenesis and the causal role of oncogenic strains of the 
HPV virus.  This understanding let to the development of two vaccines that prevent the 
two major oncogenic strains of HPV (16 and 18) which account for approximately 70% of 
all cervical cancers (Kohli et al. 2007).  Since the developed vaccines provide only a 
partial means of prevention against cervical cancer, it is essential that cervical screening is 
continued as a supplement to vaccination to provide the best possible prevention (Adams et 
al. 2007).  As a result, the proper timing of the screenings to maximize their effect towards 
combating cancer will be of interest in the post-vaccination era as well.  In fact, since the 
potential benefits of screenings will be reduced due to the reduced lifetime risk of cervical 
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cancer after vaccination, the proper timing of the screening will become even more 
important.  Furthermore, it is likely that vaccination will ultimately change the natural 
history of cervical carcinogenesis, especially if the vaccine is found not to have sustained 
lifetime immunity.  So it is of interest to see if, how, and by how much the screening ages 
that result from optimization change at different durations of sustained vaccine immunity. 
 
5.1 Calibration of Model to Incorporate Vaccination and Assumptions Made about 
the Vaccine 
        The simulation model as is now, even with calibration, cannot provide the most 
accurate projections of the natural history of cervical carcinogenesis after vaccination 
possible, to reflect the understanding of the heterogeneous role of the various oncogenic 
strains of HPV.  This is because the model does not include the appropriate HPV states in 
the natural history of cervical carcinogenesis.  Using the best available projections from the 
literature on the impact of the HPV vaccine and by considering the models used in those 
studies however, the model can be calibrated enough so that it can still provide general 
insights and projections on screening strategies that are properly timed through 
optimization in a post-vaccination era.  
           Two findings in the literature helped with the calibration of the model.  The first 
finding is that vaccination is expected to reduce cancer incidence and cancer deaths by 
approximately 70% (Kohli et al. 2007, Adams et al. 2007).  The second finding is that 
prevention from the HPV 16 and 18 strains from all oncogenic HPV strains, lowers the 
progression transition probabilities of “Well to CIN I”  and “CIN I to CIN II”.  Progression 
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transition probabilities from states CIN II onward and all regression transition probabilities 
stay the same (Goldie et al. 2003, Kohli et al. 2007).  What could not be ascertained 
however, is the relative degree to which “Well to CIN I” and “CIN I to CIN II” are 
affected.  This is because models that were used to study the vaccine also included 
transition probabilities from and to various HPV strain groups that captured the 
heterogeneous role of those strains groups towards carcinogenesis.  So, to minimize error, 
it was assumed that both transition probabilities were scaled down by the same degree.  So 
a scaling factor 0 1α≤ ≤  was introduced to the model to scale the transition probabilities 
of “Well to CIN I” and “CIN I to CIN II” so that cancer incidence and cancer deaths were 
reduced by 70% if the vaccine has sustained lifetime immunity.  As a result the calibrated 
model has biased estimates of the prevalence levels of CIN I and CIN II at different ages, 
most likely by underestimating CIN I and overestimating CIN II.  
        Current evidence from clinical trials suggest that the immunity following vaccination 
exceeds five years and appears to be sustained (Adams et al. 2007).  It is a key unknown, 
however, whether the vaccine will portray waning immunity over time.  If the vaccine does 
portray waning immunity, it is not known in what fashion the immunity of the vaccine will 
drop.  So in the model it was assumed that if waning of immunity occurs, it will drop from 
full to zero immunity with an exponential rate over a period of five years.   
 
5.2 Design of Analysis  
  The introduction of the vaccine will ultimately change the natural history of 
cervical carcinogenesis, especially if the vaccine portrays waning immunity over time.  So 
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it is of primary interest to see how the screening ages that result from optimizations will be 
affected as the duration of sustained vaccine immunity increases.  Also, due to the reduced 
risks of cervical cancer after vaccination, the potential benefits of cervical screenings will 
be reduced, along with increased negative effects on the performance of screenings, such 
as increased false positives rates.  Such effects can potentially have negative effects on 
cervical screening, such as decreased compliance by the population and an increased 
fatigue and boredom within the cytology workforce (Adams et al. 2007).  So it is also of 
interest to see how the risks of cervical carcinogenesis and the performance of screenings 
will be affected as the duration of sustained vaccine immunity increases.  With these 
objectives in mind, eight different scenarios were created where the vaccine sustains full 
immunity up to ages 20, 25, 30, 35, 40, 45, 55, and lifetime, and then immunity falls with 
an exponential rate to zero immunity over a period of five years (except for lifetime 
immunity).  On these eight scenarios, simulation optimization was applied to generate 
screening strategies with 1, 2, 3, 5, and 8 lifetime screenings available that minimize 
cancer incidence, creating 40 screening scenarios from which general conclusions can be 
drawn.  The results of all simulation optimizations are summarized in Table 13.  
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Table 13: Heuristic Optimum Solutions that Minimize Cancer Incidence with 1, 2, 3, 
5, and 8 Lifetime Screening as the Duration of Sustained Vaccine Immunity Increases 
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5.3 Results and Conclusions 
5.3.1 Observations on the Impact of Vaccination on Cervical Carcinogenesis and 
Cervical Screening 
  The first observation on the impact of vaccination on cervical carcinogenesis is that 
there are diminishing returns on the health benefits of vaccination, as the duration of 
sustained immunity increases.  This can be seen in Figure 8, where there are diminishing 
returns on the percentage reduction in cancer incidence, cancer deaths and life years lost.  
Vaccine efficacy up to age 12 depicts the case of no vaccination on figures in this chapter, 
since the body can better produce antibodies at that age and vaccination is recommended 
then for maximum immunity (Adams et al, 2007).  For example, the vaccine achieves 50% 
of its full potential (i.e., reducing cancer incidence and cancer deaths by 70%) if it has 
sustained immunity up to approximately 25 years of age and 75% of its full potential if it 
has sustained efficacy up to approximately 30 years age.  The remaining 25% of its 
potential is actualized from 30 years of age onward.  This is because the risks of HPV 
infection (and as a result the risks of CIN and Cancer) are age dependent, as they are 
directly related to sexual patterns in the population, and are higher at younger ages, 
primarily at late teens and early twenties.  
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Figure 8: Impact of Vaccine on Cancer Incidence, Cancer Deaths, and Life Years 
Lost as the Sustained Vaccine Immunity Age Increases 
 
 
The reduced lifetime risks of cervical carcinogenesis as the vaccine’s sustained 
immunity duration increases, naturally lead to a reduction of the benefits screenings can 
have towards combating cervical cancer.  Specifically, as indicated by Figure 9, the 
percentage reduction that is achieved with a specific number of lifetime screenings 
available remains approximately the same.  These percentages however, are on a 
constantly reducing cancer incidence per 100,000 as can be seen in Table 13.  One lifetime 
screening for example, prevents about 39% of all cancers when vaccine is not introduced 
to the population, when vaccine has sustained immunity up to 25 years of age, and when it 
has lifetime sustained immunity.  When the vaccine is not introduced, one lifetime 
screening averts approximately 1,190 cancers per 100,000, whereas with sustained vaccine 
immunity up to 25 years of it averts approximately 800 cancers per 100,000, and with 
lifetime sustained immunity it averts approximately 350 cancers per 100,000.  
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Figure 9: Percentage of Cancer Incidence Reduction with 1, 2, 3, 5, and 8 
Lifetime Screenings, as the Sustained Vaccine Immunity Age Increases 
 
 
In addition to the diminishing benefits of cervical screening due to reduced risks of 
cervical cancer, as the vaccine’s sustained immunity duration increases, there are also 
negative effects on the performance of screening through increased false positive rates.  
Figure 10 indicates the false positive rates for 1, 2, 3, 5, and 8 lifetime screenings, as the 
vaccine’s sustained immunity duration increases.  The increase in false positives occurs 
because with vaccination, a larger proportion of the population will not have precancerous 
lesions (CIN) or cancer. So even though the false positive rates of the screening method 
remain the same (in this case, the screening method being Pap smear with a 5% chance to 
result in a false positive), the overall chance of a false positive result increases.  
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Figure 10: False Positive Percentages with 1, 2, 3, 5, and 8 Lifetime 
Screenings, as the Sustained Vaccine Immunity Age Increases 
 
  Overall, the larger the vaccine’s sustained immunity duration, the greater (though 
diminishing) the benefits are towards combating cervical cancer.  This paradoxically has 
the potential of having a negative impact on cervical screening, which needs to be 
continued as a supplement to vaccination due to the partial protection of the vaccine.  The 
reduced lifetime risks of cervical carcinogenesis will lead to a reduction of the benefits of 
cervical screening and an increase in false positive rates.  This, as a result could potentially 
give a negative perception of cervical screening to the screened population, which can 
eventually affect the performance of screening due to reduced compliance rates. As a 
result, the value of properly timed screening strategies will be even greater in the post-
vaccination era, since as the analysis in Chapter 4 indicated, properly timed screening 
strategies provide the same health benefits as constant interval screening strategies with 
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substantially fewer screenings and fewer false positives, thereby counteracting the 
potential negative impact of vaccination towards cervical screening.  
 
5.3.2 Effects of vaccine efficacy duration to the timing of the screening strategies     
   The introduction of the vaccine will ultimately change the natural history of 
cervical carcinogenesis, so it is of interest to see how the heuristic optimum screening 
strategies that result from simulation optimization are expected to change at varying 
durations of sustained vaccine immunity.  Figures 11 and 12 indicate the pattern in which 
the screening ages are expected to change.  Figure 11 depicts how the optimal screening 
age for one lifetime screening changes as the duration of sustained vaccine immunity 
increases.  The optimal screening age with one lifetime screening without vaccination is 
35.  The optimum screening age becomes larger as the vaccine’s immunity is sustained up 
to 35 years of age, reaching 46 years of age.  As the vaccine’s immunity is sustained for 
longer periods the optimal screening age becomes smaller, eventually returning back to 35 
years of age if immunity is sustained up to 55 years of age or older.   
This pattern is maintained for the heuristic optimum screening strategies for all 
numbers of lifetime screenings tested.  Initially there is an increase on the ages where 
screening takes place until vaccine immunity is sustained up to 30 to 40 years of age.  If 
vaccine immunity is sustained for longer periods the increase grows smaller eventually 
becoming either very small or going away, if immunity is sustained up to 55 years of age 
or older.  Since it is of interest to see the pattern in which the screening ages will change 
(the model cannot definitely predict the heuristic optimum screening strategies in the post-
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vaccination era) and since there is not much variation on the change the individual 
screening ages portray for each screening strategy, the most clear way to depict this pattern 
is through the average change of the screening ages at different durations of sustained 
vaccine immunity. Figure 12 depicts the average increase of the ages in which screening 
takes place of the heuristic optimum screening strategies for 1, 2, and 3, lifetime 
screenings.  Screening strategies with 5 and 8 lifetime screenings exhibit the same pattern 
but for clarity purposes are not depicted.  
This pattern has to do with how different durations of sustained vaccine immunity 
affect the relative risks of abnormal cells (i.e., CIN I, CIN II, and CIN III).  As mentioned 
in Section 4.2, efficient screening strategies have smaller screening intervals at ages where 
the risks of CIN are higher, and larger screening intervals where the risks of CIN are lower, 
giving greater weight to more advanced levels of CIN because the more advanced CIN 
levels are the more likely they are to progress to cancer and to be detected by a Pap smear.  
If vaccination alters the ages where the risks are higher, then the heuristic optimum 
screening ages also change.  Figures A1 to A9 in Appendix A depict the change of the age-
specific risks of abnormal cells at different durations of sustained vaccine immunity and 
they indicate the same pattern the heuristic optimum screening strategies also change.  By 
looking at the CIN levels (particularly CIN II and CIN III) as the duration of sustained 
vaccine immunity gets larger up to 35 years of age, one can see that (while the absolute 
risks continuously become smaller) the relative risks are higher at older and older ages.  As 
vaccine immunity is sustained for periods longer than 35 years of age, the relative risks are 
higher at younger and younger ages. Eventually, when immunity is sustained up to age 55 
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and older, the relative risks are essentially the same as in the case of no vaccination, just 
shifted down since the absolute risks are now smaller.  
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Figure 11: Optimum Screening Age for One Lifetime Screening as the Sustained 
Vaccine Immunity Age Increases  
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Figure 12: Average Increase in Optimum Screening Ages as the Sustained Vaccine 
Immunity Age Increases  
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 An alterative way of looking at the change in the heuristic optimum screening 
strategies as the duration of sustained vaccine immunity increases is by looking at the 
difference in efficacy of the constructed (smoothed) screening strategies from no 
vaccination when applied to the different scenarios of sustained vaccine immunity, to the 
efficacy of the heuristic optimum screening strategies for each specific scenario.  Figure 13 
depicts the difference in cancer incidence of the constructed screening strategies from no 
vaccination, to the heuristic optimum screening strategies for each duration of sustained 
vaccine immunity.  Comparing the screening strategies this way, has the advantage that it 
can distinguish if the constructed screening strategies from no vaccination have 
significantly different cancer incidence from the heuristic optimum screening strategies for 
each duration of sustained vaccine immunity (“significantly different” is defined here the 
same way as in Section 4.2).  This renders the ability to distinguish if the smoothed 
screening strategies from the case of no vaccination are expected to change given the 
duration of sustained vaccine immunity.  By considering the half-widths of the heuristic 
optimum solutions from Table 13 and the cancer incidence difference from Figure 13, the 
smoothed screening strategies from the case of no vaccination are not expected to change if 
vaccine immunity is sustained up to 55 years of age or older.  It should be noted however, 
that given the limitations of this model, age 55 is the best estimate with the available data, 
for the lowest duration of sustained vaccine immunity where the smoothed screening 
strategies from the case of no vaccination are not expected to change.  
  In the cases where the screening strategies are expected to change however, it is 
worth noting that (especially when more than 3 lifetime screenings are available) the 
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changes of the optimum screening ages will not be dramatic.  This can be seen by looking 
at the screening strategies for 5 and 8 lifetime screenings for different durations of 
sustained vaccine immunity in Table 13.  There seems to be a perception however, that in 
the post-vaccination era, screening will be more important as a supplement to vaccination 
after the vaccine starts portraying waning immunity (Adams et al. 2007).  This is a crude 
way of projecting the change of screening strategies in the post-vaccination era even at the 
qualitative level.  As the 40 screening scenarios in this chapters’ analysis emphasized, 
when screening is more important is primarily related to the relative risks of CIN at 
different ages.  As a result, how screening will best supplement vaccination in the post-
vaccination era will depend on how vaccination will affect those risks.  As can be seen in 
Figures A2 to A9, even at ages where vaccination sustains its immunity, most of the times 
the risks are still higher than in ages where vaccine immunity has worn off, and that is why 
the heuristic optimum screening ages did not have dramatic changes for different durations 
of sustained vaccine immunity. 
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Figure 13: Cancer Incidence Difference of Constructed Screening Strategies from no 
Vaccination to Heuristic Optimum Screening Strategies for each Scenario of 
Sustained Vaccine Immunity 
 
5.4 Overall Conclusions  
 In the post-vaccination era, the importance of properly timed screening strategies, 
which can be attained through optimization, will be greater.  This is because the reduced 
lifetime risks of precancerous lesions and cancer will lead to a reduction of the health 
benefits of cervical screening and an increase in false positive rates.  These effects could 
potentially give a negative perception of cervical screening to the screened population 
which can lead to reduced compliance rates.  Properly timed screening strategies however, 
can counteract both these effects, since they can provide the same health benefits with 
substantially fewer screenings and false positives.  
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 Vaccination will ultimately change the natural history of cervical carcinogenesis, 
and has the potential of changing the constructed screening strategies that resulted from the 
case of no vaccination.  Analysis indicates that if the duration of sustained vaccine 
immunity does not last beyond approximately 55 years of age, the timing of the screening 
strategies is expected to change by screenings at older ages.  This change however will not 
be dramatic, especially when the number of lifetime screenings is greater than three.  This 
is because the proper timing of the screenings does not depend on the age the vaccine 
portrays waning immunity, but on the way the relative risks of CIN are affected by 
different durations of sustained vaccine immunity which will not be dramatic.
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CHAPTER 6 Concluding Remarks and Future Work 
 
6.1 Major Contributions of the Thesis 
 Cervical cancer is a leading cause of cancer related deaths among women.  Due to 
the asymptomatic nature of the disease until it is in its advanced stages, screening is of 
central importance as a means of prevention, and reduction of mortality and suffering from 
the disease.  Since the risks for cervical intraepithelial neoplasia (CIN) and cervical cancer 
vary by age, simulation optimization can be applied on models that simulate the natural 
history of cervical carcinogenesis to maximize the impact of screenings in combating 
cervical cancer, by determining the optimal ages to perform them. 
 This study demonstrated how simulation optimization can be applied on a discrete 
event simulation model to obtain efficient screening strategies that are also practical to 
serve as screening policies.  By performing optimizations for each number of lifetime 
screenings available from one to twenty two, efficient screening strategies for any given 
amount of resources available were provided.  Even though three separate sets of 
optimizations were performed (one minimizing cancer incidence, one minimizing cancer 
death and one minimizing life years lost), it was able to construct one set of screening 
strategies with objective values that were not significantly different from the heuristic 
optimum objective values with respect to all three criteria.   
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 The screening strategies that were created for each number of lifetime screenings 
available combined, resulted in the construction of an efficiency curve.  The efficiency 
curve indicated that the constant interval screening strategies were dominated by the 
constructed screening strategies which provided equal health benefits with less screenings, 
false positives, and cancer treatments.  Of particular interest were also the results for 
optimal screening strategies with small number of lifetime screenings.  Given 100% 
compliance rates by the screened population, with just one lifetime screening available, 
cancer incidence was reduced by 39%, and cancer deaths and life years lost were reduced 
by approximately 45%.  With just three lifetime screenings cancer incidence, cancer 
deaths, and life years lost were all reduced by at least 70%.  Furthermore, the screening 
strategies with seven lifetime screening reduced cancer incidence, cancer deaths, and life 
years lost by approximately 90%.  These results indicate that constructing such strategies 
through optimization for low to middle resource settings, can provide great benefits. By 
using the constructed efficiency curve, cost effectiveness analysis can be performed so that 
the most appropriate policy can be found, relative to the available recourses that can be 
applied to screening in the population of interest.   
 
6.2 Future Considerations 
 Even though the screening strategies provided in this thesis are most likely 
appropriate to at least Western European countries and the United States, the primary goal 
of this thesis was to serve as a prototype study to show how optimization can be applied to 
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provide efficient screening strategies by properly timing the screenings.  More work can be 
done in this direction when considering more specific populations of interest or more 
specific questions about screening strategies.  Some examples of possible future work can 
actually be indicated by considering some of studies already done and mentioned in the 
literature review.  
 Two such examples are the Goldie et al. (2001) and Goldie et al. (2005) studies that 
looked into cervical cancer screening policies for low-recourse settings.  By having a 
specific population of interest, the study could also consider specific costs, compliance 
levels, surveillance types, and alternative screening methods like visual inspection and 
HPV testing which seemed to offer effective screening alternatives for low resource 
settings.  By also using optimization, they would also determine the best ages the 
screenings should be performed and result to screening strategies that were even more 
cost-effective. 
  Another example was the Mandelblatt et al. (2002) study that aimed to compare the 
cost-effectiveness of various screening strategies, by considering alternative methods of 
screening.  The three screening methods that were considered where HPV DNA screening 
by itself, Pap smear by itself, and HPV DNA screening combined with Pap smear 
screening.  The study concluded that HPV testing plus Pap tests every two years appear to 
save additional life years at reasonable costs.  If in addition to the specific costs and 
efficacies of the alternative screening strategies, optimization was used to determine the 
best ages the alternative screening methods are to be performed, the results would again be 
more cost-effective strategies.  
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Furthermore, screening strategies in the post-vaccination era will have to be revised 
when more information is known about the vaccine’s impact on the natural history of 
cervical carcinogenesis, and on the vaccines efficacy over time.  As the analysis in Chapter 
5 indicated, properly timing the screenings in the post-vaccination era will be of greater 
importance due to reduced lifetime risks of precancerous lesions and cancer in the 
vaccinated population.  In general, no matter what specific questions are being considered 
regarding cervical screening, by using optimization to also determine the best ages 
screenings are to be performed, the results will always be more cost-effective. 
The improvements in cost-effectiveness for cervical cancer screening strategies 
indicate the potential benefits of properly timing the screenings for other screened diseases 
as well.  As this study indicated, the greater the costs of screening, the greater the chance 
of false positives, and the smaller the lifetime risks for contracting a disease, the greater the 
value is of properly timing the screenings for optimal performance.  Perhaps the most 
promising potential lies in breast cancer screening.  Not only breast cancer is the second 
leading cause of cancer death in women after lung cancer (NCI 2008), the timing of the 
screenings through mammography is an issue of concern.  Specifically, mammography is 
recommended and is cost-effective for women aged 50 to 69 years, but the value of 
screening mammography for age ranges 40 to 49 and 70 to 79 is an issue that is studied in 
the medical literature (Kerlikowske et al. 1999, Salzmann et al. 1997).  Such studies 
however (and other studies in the literature) also only consider a limited number of 
predetermined screening strategies when performing cost-effectiveness analysis.  Even 
though considering age ranges is an implicit way of capturing timing of the screenings, this 
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most likely will not take advantage of the natural history of breast cancer as much as 
optimization set to determine when screening should be performed.  
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APPENDIX A 
 
Age-Specific CIN Prevalence for Different Durations of Sustained Vaccine Immunity  
 
 
 
 
Figure A1: Age-specific CIN Prevalence without Vaccination 
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Figure A2: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 20 
Years of Age 
 
 
 
 
Figure A3: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 25 
Years of Age 
 
 
 
  104 
 
 
Figure A4: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 30 
Years of Age 
 
 
 
Figure A5: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 35 
Years of Age 
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Figure A6: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 40 
Years of Age 
 
 
Figure A7: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 45 
Years of Age 
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Figure A8: Age-specific CIN Prevalence for Sustained Vaccine Immunity up to 55 
Years of Age 
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Figure A9: Age-specific CIN Prevalence for Lifetime Sustained Vaccine Immunity 
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